August 2015

Quantitative Estimation of P-glycorptein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance

Alex D. Morgan
The University of Western Ontario

Supervisor
Dr. Rommel Tirona
The University of Western Ontario

Graduate Program in Pharmacology and Toxicology

A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science

© Alex D. Morgan 2015

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Part of the Pharmacology Commons

Recommended Citation
https://ir.lib.uwo.ca/etd/2961

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca.
QUANTITATIVE ESTIMATION OF P-GLYCOPROTEIN-MEDIATED DRUG TRANSPORT BY MECHANISTICALLY MODELED INTRINSIC CLEARANCE

(Thesis format: Integrated Article)

by

Alex D. Morgan

Graduate Program in Pharmacology and Toxicology

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Alex D. Morgan 2015
Abstract

P-glycoprotein (P-gp/ABCB1) is an important efflux drug transporter affecting the disposition of 50% of marketed drugs. Cell monolayer permeability assays are the gold standard for assessing P-gp-drug interactions in vitro, but inter-laboratory assay differences produce heterogeneous results. We compared the validity and sensitivity of traditional assay metrics of efflux transport (unidirectional apparent permeability and efflux ratio) with a modeled clearance metric, CL_{P-gp} and hypothesized that CL_{P-gp} would be superior. Cell monolayers heterologously transfected with ABCB1, and 1,25(OH)_{2}D_{3}-modulated ABCB1 in cells served as experimental models. P-gp expression was quantified by western blot and bidirectional [³H]-digoxin transcellular flux was measured. Linear regression analyses were performed for P-gp expression versus each P-gp activity metric. The validity and sensitivity of modeled clearance was comparable to traditional metrics within a cell type, but was superior across different cell types. In conclusion, CL_{P-gp} offers a physiologically-relevant and universally acceptable metric for efflux transport activity.

Keywords

P-glycoprotein, P-gp, modeled clearance, intrinsic clearance, apparent permeability, efflux ratio, monolayer permeability assay, efflux transporter, Caco-2, LLCPK, LMDR1
Co-Authorship Statement

For the integrated article thesis entitled “Quantitative Estimation of P-glycoprotein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance”, the following contributions were made:

Alex D Morgan and Dr. Rommel G Tirona designed the experiments. Alex D Morgan conducted the experiments. Alex D Morgan and Rommel G Tirona analyzed and interpreted the data. Alex D Morgan and Rommel G Tirona wrote the integrated article thesis.
Acknowledgments

I would like to thank my supervisor Dr. Rommel Tirona for giving me the opportunity to pursue my masters and for his continuous professional and emotional support and guidance throughout the entire process. I would not be where I am today without him.

I would like to thank the past and present members of the Kim/Tirona Lab for their support, advice and friendship during my time spent in the lab, including: Dr. Wendy Teft, Dr. Inna Gong, Dr. Marianne Degorter, Ms. Sarah Woolsey, Mr. Colin Suen, Ms. Sara Mansell LeMay, Mr. Cameron Ross, Ms. Matilde Leon-Ponte, Dr. Ute Schwarz, Mr. David Sheshelidz, Dr. Daisuke Sugiyama, Dr. Hidenori Takada, Dr. Murray Cutler, Dr. Crystal Schmerk, Mr. Peter Yin, Mr. Markus Gulilat, Ms. Cheynne Mclean, Ms. Mandy Li and especially Dr. Michael Knauer, to whom I owe so much of my success.

I would like to thank my advisory committee, Dr. Richard Kim, Dr. Timothy Regnault, Dr. Sean Cregan and Dr. David Freeman for their guidance throughout this process.

Finally, words cannot express my gratitude towards my parents, Dunstan and Beverley, my siblings Cynthia and Anthony, and my dearest friends Sarah Chung and Ashbeel Roy. They have been my strength and continue to support me in all of my endeavors.
# Table of Contents

Abstract ............................................................................................................................... ii  
Co-Authorship Statement .................................................................................................. iii  
Acknowledgments .............................................................................................................. iv  
Table of Contents ................................................................................................................ v  
List of Tables ....................................................................................................................... ix  
List of Figures ..................................................................................................................... x  
Abbreviations .................................................................................................................... xii  
Chapter 1 ............................................................................................................................. 1  
Introduction ......................................................................................................................... 1  
  1.1 Pharmacokinetics ....................................................................................................... 1  
  1.1.1 Absorption, distribution, metabolism and elimination (ADME) ....................... 1  
  1.1.2 Interindividual variation in ADME ........................................................................ 3  
  1.2 Transporters ............................................................................................................... 4  
  1.2.1 Transporters ......................................................................................................... 4  
  1.2.1.1 Physiological and pharmacological role ........................................................... 4  
  1.2.1.2 Structure and function ...................................................................................... 5  
  1.2.2 P-glycoprotein/MDR1 ......................................................................................... 6  
  1.2.2.1 Discovery and Cloning of P-gp ................................................................. 6  
  1.2.2.2 Biochemistry (structure, substrates and function) ...................................... 7  
  1.2.2.3 Tissue expression and role in absorption, distribution and elimination ....... 8  
  1.2.2.4 Gene regulation .............................................................................................. 9  
  1.2.2.5 Relevance of P-gp to clinical pharmacology ............................................. 10  
  1.2.2.6 Relevance to drug development ................................................................. 18
3.1 Study Objective ....................................................................................................... 117
3.2 Monolayer permeability assay metrics of P-gp activity ........................................ 117
3.3 Standardizing monolayer permeability assays ..................................................... 119
3.4 Applying monolayer permeability assay data to drug discovery and development ............................................................................................................................. 120
3.5 Applying monolayer permeability assay data to IVIVE ....................................... 121
3.6 Limitations of the experimental approach to estimate CL_{P-gp} (model assumptions) ........................................................................................................................................ 122
3.7 Recommendations/future studies ........................................................................ 123
3.8 Overall conclusion ............................................................................................... 124
3.9 References ......................................................................................................... 125
Curriculum Vitae ......................................................................................................... 131
List of Tables

Table 1.1 P-glycoprotein substrates ................................................................. 11

Table 1.2 P-gp substrates and inhibitors .......................................................... 13

Table 1.3 Clinical genetic polymorphisms in MDR1 ....................................... 15

Table 2.1 Transwell monolayer inulin permeabilities ....................................... 78

Table 2.2 Transwell monolayer P-gp and Actin expression levels .................... 85

Table 2.3 Calculated $P_{\text{app}}$, $E_{\text{fR}}$, and $CL$ values for LLCPK and LMDR1 monolayers. .......... 96

Table 2.4 Calculated $P_{\text{app}}$, $E_{\text{fR}}$ and $CL$ values for Caco-2 (0 nM), (10 nM), and (100 nM) monolayers ................................................................................................................................. 97

Table 2.5 Summary of goodness of fit ($r^2$) and regression slopes (m) for regression analyses of different estimates of P-gp activity with P-gp expression ...................................................... 107
List of Figures

Figure 1.1. Simplified general scheme of quantitative IVIVE. Error! Bookmark not defined. 22

Figure 1.2. Schematic depiction of the physiological model for liver clearance described by Sirianni and Pang, 1997 25

Figure 1.3 The cell monolayer permeability assay 31

Figure 1.4 Schematic depiction of cytochrome P450-expressing Caco-2 cell monolayer under linear conditions described by Tam et al., 2003 34

Figure 1.5. Putative transporters expressed in cultured Caco-2 cells 36

Figure 2.1 Schematic presentation of our compartmental model 71

Figure 2.2 The cytotoxic effect of vitamin D (1,25(OH)_{2}D_{3}) on cultured Caco-2 cells 79

Figure 2.3 [^{3}H]-Digoxin bidirectional flux across LLCPK and LMDR1 monolayers 80

Figure 2.4 [^{3}H]-Digoxin bidirectional flux across Caco-2 (0 nM), (10 nM), and (100 nM) monolayers 81

Figure 2.5 P-gp western blots for LLCPK, LMDR1, and Caco-2 (0 nM), (10 nM), and (100 nM) experiment monolayers 83

Figure 2.6 [^{3}H]-Digoxin A-B and B-A apparent permeability values for LLCPK, LMDR1, and Caco-2 (0 nM), (10 nM), and (100 nM) monolayers 87

Figure 2.7 [^{3}H]-Digoxin efflux ratio LLCPK, LMDR1, and Caco-2 (0 nM), (10 nM), and (100 nM) monolayers 88

Figure 2.8 Model fitting of inulin transport across LLCPK, LMDR1, and Caco-2 (0 nM), (10 nM), and (100 nM) monolayers 90
Figure 2.9 Model fits of \(^{3}H\)-digoxin transwell transport across LLCPK and LMDRI cell monolayers .......................................................... 92

Figure 2.10 Model fits of \(^{3}H\)-digoxin transwell transport across Caco-2 (0 nM), (10 nM), and (100 nM) cell monolayers .......................................................... 93

Figure 2.11 Modeled CL\(_{P-gp}\), CL\(_{A-C}\), CL\(_{C-B}\), and CL\(_{A-B}\) of bidirectional \(^{3}H\)-digoxin transport across LLCPK, LMDRI, and Caco-2 (0 nM), (10 nM), and (100 nM) monolayers .......... 95

Figure 2.12 Normalized P\(_{app(A-B)}\) coefficients vs. normalized P-gp expression for LLCPK and LMDRI data alone, for Caco-2 (0 nM), (10 nM) and (100 nM) data alone, and for all data combined .......................................................................................................................... 100

Figure 2.13 Normalized P\(_{app(B-A)}\) coefficients vs. normalized P-gp expression for LLCPK and LMDRI data alone, for Caco-2 (0 nM), (10 nM) and (100 nM) data alone, and for all data combined .......................................................................................................................... 102

Figure 2.14 Normalized EfR coefficients vs. normalized P-gp expression for LLCPK and LMDRI data alone, for Caco-2 (0 nM), (10 nM) and (100 nM) data alone, and for all data combined .......................................................................................................................... 104

Figure 2.15 Normalized CL\(_{P-gp}\) coefficients vs. normalized P-gp expression for LLCPK and LMDRI data alone, for Caco-2 (0 nM), (10 nM), and (100 nM) data alone, and for all data combined .......................................................................................................................... 106
Abbreviations

\textit{ABCB1} \hspace{1cm} \text{ATP-binding cassette, subfamily B, member 1}

ADME \hspace{1cm} \text{Absorption, distribution, metabolism, elimination}

AUC \hspace{1cm} \text{Area under the curve}

BCRP \hspace{1cm} \text{Breast cancer resistance protein}

BBB \hspace{1cm} \text{Blood-brain barrier}

BSP \hspace{1cm} \text{Bromosulfophthalein}

C_u \hspace{1cm} \text{Unbound (free) drug concentration}

Caco-2 \hspace{1cm} \text{Human colorectal adenocarcinoma cell line}

Caco-2 (0 nM) \hspace{1cm} \text{Untreated Caco-2 cells}

Caco-2 (10 nM) \hspace{1cm} \text{Caco-2 cells treated with 10 nM 1,25(OH)_{2}D}_{3}

Caco-2 (100 nM) \hspace{1cm} \text{Caco-2 cells treated with 100 nM 1,25(OH)_{2}D}_{3}

Calcitriol \hspace{1cm} \text{1,25-dihydroxycholecalciferol or 1,25-dihydroxyvitamin D}_{3}

CAR \hspace{1cm} \text{Constitutive androstane receptor}

CL \hspace{1cm} \text{Clearance}

CL_{int} \hspace{1cm} \text{Intrinsic clearance}

CL_{int(Metabolism)} \hspace{1cm} \text{Intrinsic metabolic clearance}

CL_{int(Transport)} \hspace{1cm} \text{Intrinsic carrier-mediated clearance}

CL_{P-gp} \hspace{1cm} \text{P-gp intrinsic clearance}

CL_{plasma} \hspace{1cm} \text{Systemic plasma clearance}
\( C_{\text{max}} \)  
Peak serum concentration

CNS  
Central nervous system

CNV  
Copy number variation

\( C_p^{\text{ss}} \)  
Steady-state plasma concentration

CYP  
Cytochrome P450

DDD  
Drug discovery and development

DDI  
Drug-drug interaction

DME  
Drug metabolizing enzyme

DMEM  
Dulbecco’s modified Eagle’s medium

DMSO  
Dimethyl sulfoxide

EfR  
Efflux ratio

F  
Bioavailability

FBS  
Fetal bovine serum

FDA  
Food and Drug Administration

FXR  
Farnesoid X receptor

GST  
Glutathione S-transferase

HPT1  
Human peptide transporter 1

IV  
Intravenous

IVIVE  
\textit{In vitro to in vivo} extrapolation

KHB  
Krebs-Henseleit Bicarbonate Buffer
$K_m$  Michaelis-Menten constant

LLCPK  Porcine kidney epithelial cell line

LMDR1  LLCPK overexpressing MDR1

$m$  Slope

MATE  Multidrug and toxin extrusion transporter

MDCK  Madin-Darby canine kidney cell line

MDR1  Multi-drug resistance protein 1

MRP  Multidrug resistance-associated protein

MTT  Thiazolyl blue tetrazolium bromide

NEAA  Nonessential amino acids

NCE  New chemical entity

NDA  New drug application

OAT  Organic anion transporter

OATP  Organic anion-transporting polypeptide

OCT  Organic cation transporter

OST$\alpha$  Organic solute transporter $\alpha$

OST$\beta$  Organic solute transporter $\beta$

$P_{\text{app}}$  Apparent permeability

$P_{\text{app(A-B)}}$  Apical to basolateral apparent permeability

$P_{\text{app(B-A)}}$  Basolateral to apical apparent permeability
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBPK</td>
<td>Physiologically-based pharmacokinetics</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>PepT1</td>
<td>Peptide transporter 1</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetic(s)</td>
</tr>
<tr>
<td>P.O.</td>
<td>Per os/Oral ingestion</td>
</tr>
<tr>
<td>PXR</td>
<td>Pregnane X receptor</td>
</tr>
<tr>
<td>RXR</td>
<td>Retinoic acid receptor</td>
</tr>
<tr>
<td>SLC</td>
<td>Solute-carrier group of membrane transporters</td>
</tr>
<tr>
<td>SNP</td>
<td>Single nucleotide polymorphism</td>
</tr>
<tr>
<td>TEER</td>
<td>Transepithelial electrical resistance</td>
</tr>
<tr>
<td>V\textsubscript{d}</td>
<td>Volume of distribution</td>
</tr>
<tr>
<td>VDR</td>
<td>Vitamin D receptor</td>
</tr>
</tbody>
</table>
Chapter 1

Introduction

1.1  Pharmacokinetics

Pharmaceutical agents act on various molecular targets throughout the body. A particular concentration of unbound drug must be achieved at a given site of action for a drug to produce its intended pharmacological effect. However, a much lower level of drug will not produce the desired therapeutic effect and a much higher level can be associated with toxicity. Therefore, drug concentration present at different sites is a critical determinant of the pharmacological efficacy of any drug therapy.

Pharmacokinetics (PK) is a branch of pharmacology that examines the interplay between drug properties and physiological processes in the body to dictate circulating drug levels over time.

1.1.1  Absorption, distribution, metabolism and elimination (ADME)

The pharmacokinetic processes can be broken down into absorption, distribution, metabolism, and elimination (excretion), given the common acronym ADME. Absorption refers to the pharmacokinetic processes involved in the movement of administered drugs into the systemic circulation and the bioavailability of a drug describes the fraction of an administered dose that actually reaches the systemic circulation unchanged. Any drug that is not injected directly into the blood stream by intravenous (IV) administration must cross at least one cell membrane barrier to enter the circulation. Permeability across any cell membrane is a function of the physiochemical properties of both the drug (i.e. molecular size, shape, ionization, and lipid solubility) and the membrane (e.g. protein channels and drug transporters). Drug movement may occur via passive diffusion through the lipid membrane and/or via carrier-mediated transport. Many primary active transporter proteins show unidirectional transport activity and depending on their orientation in polarized epithelia, they may either facilitate or oppose absorption from the GI tract and other body compartments. Since the vast majority of drugs are administered by oral dose (per os), factors affecting GI drug absorption are of particular therapeutic concern.
During the *distribution* phase, a drug achieves a certain concentration in the blood (C_{Plasma}), which changes over time. Transporters expressed in various tissues of the body may play a role in the selective accumulation and distribution of drugs into target tissues.

The term volume of distribution (V_d) describes overall how well a drug distributes from the blood into body tissues.

Chemical modification, or *metabolism*, of parent drugs occurs primarily in the liver to produce metabolites of increased polarity. Many of the metabolic reactions are mediated by a class of heme-containing enzymes found in the hepatocyte endoplasmic reticulum, which are known as the cytochrome P450 superfamily of oxygenases (CYP). There are 57 genes and over 59 pseudogenes in humans, divided among 18 families and 43 subfamilies by sequence homology (1). The CYP 1 to 3 families are the biggest contributors to drug metabolism in humans. In particular, cytochrome P450 family 3, subfamily A, member 4 (CYP3A4) metabolizes as many as 50 percent of drugs on the market and is the most clinically relevant of the CYP isoforms (1;2).

Polar parent drugs and metabolites are *eliminated* by passive filtration into the urine or by carrier-mediated transport into the urine or stool. Plasma clearance (CL_{plasma}) represents the irreversible removal of a drug from the plasma, as a volume cleared per unit time, and it is the summation of elimination processes in the body. CL_{plasma} can be determined from the area under the plasma concentration curve (AUC) following a single IV dose as Dose/AUC. The half-life (t_{1/2}) of a drug – the amount of time it takes for drug concentrations in blood to decline by 50 percent – also relates to the plasma clearance and volume of distribution by the following relationship:

\[
t_{1/2} = 0.693 \times \frac{V_d}{CL}
\]  

For multiple dosing, C_{Plasma} oscillates with each dose until an average steady-state plasma concentration (C_{p,ss}) is reached when the rate of administration is equal to the rate of elimination.

At steady state:
\[ \frac{D}{\tau} = \text{CL} \times C_p^{ss} \]  \hspace{1cm} [1.2]

where,

Rate of drug administration = \( \frac{D}{\tau} \)  \hspace{1cm} [1.3]

Rate of drug elimination = \( \text{CL}_{\text{plasma}} \times C_p^{ss} \)  \hspace{1cm} [1.4]

The drug dose (D) and dosing frequency (\( \tau \)) are selected inversely proportional to the \( \text{CL}_{\text{plasma}} \), such that the \( C_p^{ss} \) of a drug remains within the therapeutic range.

### 1.1.2 Interindividual variation in ADME

As suggested in Section 1.1.1, drug transporters and drug metabolizing enzymes (DMEs) play a critical role in ADME processes. Accordingly population variations in these ADME proteins can account for striking differences observed in the way that certain individuals or populations handle a particular drug (3; 4). For many drugs, pharmacokinetics and thus optimal dosing can vary significantly between patients; the standard dosing regimen may fail to reach a therapeutic level in some individuals or may exhibit dose-dependent toxicity in others. This is of particular concern for drugs with a narrow therapeutic index (the ratio between the therapeutic dose and the toxic dose).

Both genetic and environmental factors can contribute to the variations in ADME protein activity and expression that are responsible for population pharmacokinetic variability. Genetic polymorphisms are DNA sequence variants that naturally occur at a given genome locus in more than 1% of the population and are not due to recurrent mutations. They may be in the form of a single substituted, inserted or deleted nucleotide base (a single nucleotide polymorphism or SNP), or a larger segment of DNA that is present in irregular frequency (copy number variation or CNV). Polymorphisms appear broadly throughout the human genome and many polymorphic sites have been shown to impact the expression and/or function of a variety of gene products, including several key drug metabolizing enzymes and transporters (4-6).
Exposure to xenobiotics can also produce significant interindividual variation in the activity and expression of drug metabolizing enzymes and drug transporters. A drug interaction is said to have occurred when the presence of foods, dietary supplements, other drugs or drug diluents cause variation in drug response. Co-administered compounds may bind an enzyme or transporter to cause a concentration-dependent decrease in enzyme or transporter activity. They may also inhibit or induce ADME protein activity by modulating gene expression via transcriptional mechanisms involving nuclear hormone receptors. Those interactions that result specifically from the presence of a second drug, termed drug-drug interactions (DDIs), have been a recognized obstacle to successful drug therapy since the 1960s (7; 8).

As a result of the ever-growing list of clinically relevant genetic polymorphisms and drug-drug interactions, many drug regulatory agencies, including the FDA, offer recommendations for routine assessment and management of polymorphisms and DDIs during drug discovery, drug development and clinical drug use. Pharmacogenomic and drug-drug interaction studies have become critical in the selection of new chemical entities with desirable pharmacokinetics and in elucidating the mechanisms underlying observed preclinical and clinical drug levels. It is important to know how extensively particular polymorphisms and DDIs alter the expression and or activity of ADME proteins and to know how this information translates into the clinical setting.

1.2 Transporters

1.2.1 Transporters

1.2.1.1 Physiological and pharmacological role

Transporters are transmembrane proteins that are expressed in the various tissues of the body to facilitate the movement of important endogenous compounds across the cell plasma membrane. Endogenous substrates include inorganic ions, amino acids, sugars and nucleotides. However, substrate specificity is not limited to physiological compounds. Many transporters, in fact, recognize a variety of structurally diverse xenobiotics including environmental compounds, dietary compounds, drugs and drug metabolites. Transporters can thus have an important role in pharmacokinetics and
therapeutic efficacy and can be a mechanism for interindividual variability, interspecies variability and drug-drug interactions.

1.2.1.2 Structure and function

Due to their hydrophobic nature, relatively low abundance, and inherently flexible structure, molecular identification of transporters was difficult to accomplish until the development of modern expression cloning techniques in the early 1990s. Three dimensional crystal structures have only been achieved at atomic resolution for a limited number of transporters thus far. Nonetheless, drug transporters can be categorized molecularly into two major groups: the ATP-binding cassette (ABC) and the solute carrier (SLC) superfamilies of transporters. In humans, the ABC superfamily is comprised of 7 families with 48 known members (9; 10). These transporters have an ATP-binding domain that binds and hydrolyzes ATP to power active transport of substrates against a concentration gradient. The most well characterized members of this superfamily are the \textit{ABCB1} and ABCG2 members known as P-glycoprotein/multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP) respectively. The SLC superfamily is comprised of 55 families, with approximately 362 known members (11). These transporters do not have an ATP-binding domain, but instead use an ion gradient to power active transport of their substrates. Important SLC drug transporters are the organic anion-transporting polypeptide 1B1 (OATP1B1), the organic anion-transporting polypeptide 1B3 (OATP1B3), the organic anion transporter 1 (OAT1) the organic anion transporter 3 (OAT3), and the organic cation transporter 2 (OCT2) (12). Respectively, these transporters are the \textit{SLCO1B1, SLCO1B3, SLC22A6, SLC22A8}, and \textit{SLC22A2} members of the solute-carrier transporter family.

In addition to molecular categorization, transporters can also be grouped by their function. Uptake transporters move substrates from the extra cellular space into the cell cytoplasm. This is more common among SLC drug transporters. Conversely, efflux transporters extrude substrates into the extracellular environment, which is more common among, but not limited to, the ABC drug transporters. Quite often, uptake and efflux transporters coordinate activity for the asymmetrical transport of endogenous compounds, drugs, or toxins across an epithelial or endothelial barrier of cells (13). This kind of
vectorial transport is how polarized cells can facilitate passage of both hydrophilic and lipophilic compounds across biological membranes to contribute to drug absorption, distribution and elimination, as alluded to in Section 1.1.1.

Vectorial transport is possible because of overlap in the substrate specificities of different uptake and efflux transporters. For example, in a model of the blood to bile hepatic secretion of organic anions, Cui et al. showed vectorial transport of sulfobromophthalein (BSP) across a membrane of polarized Madin-Darby canine kidney (MDCK) cells that were double-transfected with organic anion transporter 1B3 (OATP1B3; SLC member SLCO1B3) and multidrug resistance-associated protein 2 (MRP2; ABC member ABCC2) (14). The cells demonstrated basolateral OATP1B3 uptake and subsequent apical MRP2 efflux of BSP. For highly lipophilic compounds with sufficient membrane permeability, unidirectional ABC efflux transporters are able to achieve vectorial transport across a polarized plasma membrane without coordinated influx by an uptake transporter (15). But, coordination of uptake and efflux transporters is necessary for the vectorial transport of more hydrophilic compounds. Consequently, a variety of different uptake and efflux transporters are expressed on either membrane of the polarized epithelial or endothelial cells of several organs. This includes intestinal epithelia, hepatocyte epithelia, kidney proximal tubule epithelia, and endothelial cells of the blood-brain barrier.

1.2.2 P-glycoprotein/MDR1

The role of transporters in pharmacokinetics is a maturing area of investigation and the important pharmacokinetic impacts of many transporters have yet to be fully elucidated. P-glycoprotein was among the first transporters to be studied; it is the most well characterized transporter to date and it was the first transporter protein recommended for regular pharmacokinetic testing by the FDA (16-18).

1.2.2.1 Discovery and Cloning of P-gp

In 1960, acquired resistance to actinomycin D was reported in HeLa cell lines (19) and then later in Chinese hamster ovary cells (20). These cells were shown to possess multidrug resistance and subsequently Dano et al. demonstrated active efflux of daunomycin in the cells by a proposed efflux pump (21). Juliano and Ling named the
pump permeability-glycoprotein (P-glycoprotein or P-gp), for its ability to alter the permeability of mutant cells (22). In the following decade, Riordan and his group were the first to clone the gene for P-glycoprotein (23). By 1987, it became apparent that P-gp is physiologically expressed in normal human excretory and barrier tissues, such as the intestine, liver, kidney and the blood brain barrier (24-34). Ultimately, P-gp was defined as a primary efflux pump that uses the energy from ATP hydrolysis to actively extrude its substrates from cells (35). The gene for the transporter was originally called multidrug resistance gene (MDR1) because of the multidrug resistance phenotype it conferred to tumour cells, but has since been classified as \textit{ABCB1} (member 1 of the B subfamily in the ATP-binding cassette transporter superfamily). In 2009, the P-gp x-ray crystal structure was revealed for better characterization of substrate-binding and solute translocation mechanism of this key drug transporter (36). Today, P-gp remains the most well studied and well characterized drug transporter in humans.

\textbf{1.2.2.2 Biochemistry (structure, substrates and function)}

P-gp is a 170 kDa protein composed of 1280 amino acids. Its quaternary protein structure is organized as 2 homologous halves, each with an intracellular nucleotide binding domain and a bundle of 6 hydrophobic transmembrane \(\alpha\)-helices (36-39). N-glycosylation occurs at the first extracellular loop and the 2 halves are linked by a highly charged and phosphorylated region. The linking region contains signature motifs that are characteristic of the ABC transporter family. Collectively, the transmembrane segments form a central internal cavity where multiple sites are found for substrate and modulator binding (36). This binding pocket is substantially larger than most transporters and can even accommodate 2 substrates simultaneously (40). Additionally, substrate binding in the pocket produces size- and shape-dependent conformational changes of the transmembrane segments, alluding to an induced-fit for substrate binding (40). Taken together, some of these structural characteristics may explain the incredibly broad substrate specificity observed for the P-gp transporter.

P-gp transports a wide variety of structurally and functionally diverse compounds including: opioids, steroids, antibiotics, calcium-channel blockers, chemotherapeutics, immunosuppressants, anti-HIV drugs, linear and cyclic peptides, ionophores, bilirubin,
and many others (41) (Table 1.1). Many P-gp substrates are nonpolar, weakly amphipathic compounds and contain planar aromatic rings and positively charged tertiary nitrogens. However, there are no clearly defined recognition elements that are highly conserved among all P-gp substrates and modulators. It is worth noting though, that many of P-gp’s substrates are also found to be substrates of the CYP3A4 enzyme, suggesting MDR1 and CYP3A4 have a synergistic protective role to reduce the intestinal absorption of xenobiotics (42-44; 5).

P-glycoprotein functions as a unidirectional lipid flipase (45). Substrate binding initiates ATP-binding, which causes dimerization of the nucleotide binding domains (NBD), which results in a large structural change of the transporter protein into its outward facing conformation. The substrate is then released into extracellular space as ATP is hydrolyzed. Simultaneously, the ATP hydrolysis disrupts the NBD dimerization, hence causing P-gp to revert back to its original inward facing conformation (46). In P-gp’s active conformation, the internal cavity formed by the transmembrane helices, is oriented inward, open to both the cytoplasm and the inner membrane leaflet (47). Substrates in the outer membrane leaflet and the extracellular space do not have direct access to the pocket (36; 48) and P-gp extrudes its substrates directly from the inner leaflet; this is a common feature among transporters with a binding site located in a transmembrane domain of α-helices. Many P-gp substrates readily partition into the plasma membrane and require association with lipids for drug-stimulated ATPase activity (49).

1.2.2.3 Tissue expression and role in absorption, distribution and elimination

Cells that express P-gp extrude substrates directly from the membrane, thereby preventing substrate drugs and toxins from entering the cell. Immunohistochemical analysis has indicated that human P-gp is expressed typically at the apical membrane of polarized cells in several tissues with barrier functions (e.g. small intestine, blood-brain barrier, blood-testis barrier, blood-ovarian barrier and placenta) or secretory functions (e.g. liver, kidney and adrenal gland) (50; 51; 44; 52-54). The greatest MDR1 expression is found in the intestinal epithelia; again indicating an important role of P-gp in modulating intestinal absorption. Indeed, induction of intestinal P-gp by the antibiotic rifampin correlated with a significant decrease in the AUC of orally administered
digoxin, a P-gp substrate, in humans (55). Beyond this, P-gp is apically expressed in liver and kidney epithelia, and on the blood side of brain capillary endothelial cells. It plays a significant role in the biliary and urinary excretion of various drugs and is known to limit central nervous system (CNS) penetration, as part of the blood-brain barrier (26; 56).

Despite the broad activity of P-gp, the Collie dog breed and a substrain of the CF-1 mouse are viable and fertile even though they are both naturally devoid of any P-gp expression (57-59). From this it can be concluded, in dogs and mice at least, that P-gp does not carry an essential physiological function. However, no human null allele has ever been reported for P-glycoprotein to date. Also of note, collie dogs and CF-1 mice do show significantly heightened sensitivity to drug and xenobiotic exposure; this once again emphasizing the important protective role of P-gp in the body (58-60).

1.2.2.4 Gene regulation

For decades, it has been well appreciated that the body mounts an adaptive response when exposed to xenobiotics, which is meant to limit exposure to toxic compounds. Indeed, in 1963 Cucinell et al. first reported decreased concentrations of phenytoin and coumarin in humans treated with phenobarbital; likely in response to upregulation of drug metabolizing enzymes (61-63). This kind of ADME protein regulation occurs via ligand-activated nuclear receptor signaling. In the case of most nuclear receptors, the receptor binds its ligand in the cytoplasm and then translocates to the nucleus, where it forms a heterodimer with the 9-cis retinoic acid receptor (RXR). The formed heterodimer complex may bind in the regulatory region of a given ADME protein gene, thereby affecting the binding and recruitment of co-repressor and co-activator proteins, which suppress and stimulate gene transcription respectively (64).

The transcription of many drug metabolizing enzymes has been shown to be modulated in response to xenobiotic ligands that bind the nuclear receptors: Pregnane X Receptor (PXR) (65-69), Constitutive Androstane Receptor (CAR) (70-73), Vitamin D Receptor (VDR) (74; 75), Farnesoid X Receptor (FXR) (76-78) and others.

It is only in the past 2 decades or so that regulation of drug transporters by the same nuclear receptor mechanisms has gained attention as part of a coordinated response to
xenobiotic toxic exposure. The P-gp transporter was shown to be regulated by PXR, similar to CYP3A4 (43). Both PXR and CAR binding sites are located in an ABCB1 regulatory region 8 kb upstream of the MDR1 gene transcription start site (80; 81). P-gp has also been shown to be regulated by Vitamin D. When testing for substances that can induce CYP3A4 expression in Caco-2 cells, Schmiedlin-ren et al. observed an increase in P-gp expression after treating cells with 0.05 µM – 1 µM 1,25(OH)_2D_3, and ≥ 0.5 µM and ≥ 2.5 µM 25-(OH)-D_3 (82). Thummel et al. later demonstrated similar vitamin D modulation of P-gp in Caco-2 cells and LS180 human colon carcinoma cells by 50-1000 nM 1,25(OH)_2D_3; with a lower limit of induction at 1 nM and an upper limit at 250 nM (83). Eventually the vitamin D response elements were identified in the human MDR1 promoter between -7880 and -7810 bp upstream of the MDR1 gene, where the VDR/RXRα heterodimer binds to induce transcription (84). Fan et al. has since confirmed that vitamin D and associated analogues induce P-gp mRNA, protein, and transport activity in a human colorectal adenocarcinoma (Caco-2) cell monolayers (85).

1.2.2.5 Relevance of P-gp to clinical pharmacology

A large number of chemically diverse drugs have been demonstrated to interact with P-gp (Tables 1.1 and 1.2) and thus P-gp has the potential to contribute to a great many clinically significant drug-drug interactions. For example, in a study of healthy volunteers, Schwarz et al. showed respectively a 52% and 26% increase in the AUC and peak plasma concentration of a prototypical P-gp substrate, talinolol, in response to concomitant administration of the P-gp inhibitor erythromycin (86). This study notwithstanding though, much of the evidence for clinical drug interactions mediated by P-gp is derived indirectly from in vitro studies or from animal studies; and few clinically relevant DDIs have actually been attributed solely to P-gp. One significant reason for this is the extensive overlap in substrate selectivity, tissue localization, and gene modulation profile that is shared between MDR1 and CYP3A4 (87). It can be difficult to distinguish the in vivo contributions of metabolism and transport to DDIs; and metabolism is often assumed the major cause of DDI, particularly for substrates with fair or extensive metabolism. However, DDIs involving poorly metabolized P-gp substrates and potent and selective P-gp modulators have been linked more unambiguously to P-gp (88; 55;
<table>
<thead>
<tr>
<th>Substrate</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticancer agents</strong></td>
<td></td>
</tr>
<tr>
<td>Actinomycin D</td>
<td>Jette et al., 1995</td>
</tr>
<tr>
<td>Daunorubicin</td>
<td>Sharpio and Ling, 1998</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>Wils et al., 1994</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>Sharpio and Ling, 1998</td>
</tr>
<tr>
<td>Etoposide</td>
<td>Sharpio and Ling, 1998</td>
</tr>
<tr>
<td>Imatinib</td>
<td>Widmer et al., 2003</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>Arimori et al., 2003</td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>Relling, 1996</td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>Relling, 1996</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>Sparreboom et al., 1997</td>
</tr>
<tr>
<td>Teniposide</td>
<td>Relling, 1996</td>
</tr>
<tr>
<td>Topotecan</td>
<td>Relling, 1996</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>Wils et al., 1994</td>
</tr>
<tr>
<td>Vincristine</td>
<td>Relling, 1996</td>
</tr>
<tr>
<td><strong>Antihypertensive agents</strong></td>
<td></td>
</tr>
<tr>
<td>Celiprolol</td>
<td>Karlsson et al., 1993</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>Saeki et al., 1993</td>
</tr>
<tr>
<td>Losartan</td>
<td>Soldner et al., 2000</td>
</tr>
<tr>
<td>Talinolol</td>
<td>Wetterich et al., 1996</td>
</tr>
<tr>
<td><strong>Antiarrhythmics</strong></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>de Lannoy and Silverman, 1992</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Kim et al., 1999</td>
</tr>
<tr>
<td>Verapamil</td>
<td>Kim, 2002</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Taubert et al., 2006</td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>Teng et al., 2010</td>
</tr>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td></td>
</tr>
<tr>
<td>Aldosterone</td>
<td>Ueda et al., 1992</td>
</tr>
<tr>
<td>Cortisol</td>
<td>Ueda et al., 1992</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Ueda et al., 1992</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>Saitoh et al., 1998</td>
</tr>
<tr>
<td><strong>Oral anticoagulants</strong></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>Schulman et al., 2010</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Walenga and Adiguzel, 2010</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Gnoth et al., 2011</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Warson et al., 2011</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>Mendell et al., 2011</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
</tr>
<tr>
<td>Atrovastatin</td>
<td>Wu et al., 2000</td>
</tr>
<tr>
<td>Colchicine</td>
<td>Kim, 2002</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>Cvetkovic et al., 1999</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>Didier and Loof, 1995</td>
</tr>
<tr>
<td>Loperamide</td>
<td>Schinkel et al., 1996</td>
</tr>
<tr>
<td>Melfoquine</td>
<td>Pham et al., 2000</td>
</tr>
<tr>
<td>Rhodamine 123</td>
<td>Kim, 2002</td>
</tr>
<tr>
<td>Terfenadine</td>
<td>Kim et al., 1999</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>Smit et al., 1998</td>
</tr>
<tr>
<td><strong>Antiviral agents</strong></td>
<td></td>
</tr>
<tr>
<td>Amprenavir</td>
<td>Polli et al., 1999</td>
</tr>
<tr>
<td>Medicine</td>
<td>Author(s)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Indinavir</td>
<td>Kim et al., 1998</td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>Kim et al., 1998</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>Kim et al., 1998</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Kim et al., 1998</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Schuetz et al., 1998</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Ito et al., 1997</td>
</tr>
<tr>
<td>Rifampin</td>
<td>Schuetz et al., 1996</td>
</tr>
<tr>
<td>Sparfloxacin</td>
<td>Tamai et al., 2000</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Kavallaris et al., 1993</td>
</tr>
<tr>
<td><strong>Antimycotics</strong></td>
<td></td>
</tr>
<tr>
<td>Intraconazole</td>
<td>Miyama et al., 1998</td>
</tr>
<tr>
<td><strong>Immunosuppressants</strong></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Schinkel et al., 1996</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Paine et al., 2002</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Saeki et al., 1993</td>
</tr>
<tr>
<td>Valsparodar</td>
<td>Tai, 2000</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Uhr et al., 2000</td>
</tr>
<tr>
<td><strong>Antiepileptics</strong></td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>Potschka et al., 2002</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Schinkel et al., 1996</td>
</tr>
<tr>
<td><strong>Antiacids</strong></td>
<td></td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Collett et al., 1999</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>Collett et al., 1999</td>
</tr>
<tr>
<td><strong>Opioids</strong></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td>Callagan and Riordan, 1993</td>
</tr>
<tr>
<td><strong>Antiemetics</strong></td>
<td></td>
</tr>
<tr>
<td>Domperidon</td>
<td>Schinkel et al., 1996</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>Schinkel et al., 1996</td>
</tr>
</tbody>
</table>
Table 0.2. Drugs shown in clinical and/or in vitro study to affect the pharmacokinetics of a P-gp probe substrate by inhibition or induction of P-gp.

<table>
<thead>
<tr>
<th>Interacting Drug</th>
<th>Inhibitor/Inducer</th>
<th>Substrate(s)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihypertensive agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carvedilol</td>
<td>Inhibitor</td>
<td>vinblastine, paclitaxel, doxorubicin, daunorubicin</td>
<td>kakumoto <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Nicardipine</td>
<td>Inhibitor</td>
<td>daunorubicin, digoxin</td>
<td>Katoh <em>et al.</em>, 2000</td>
</tr>
<tr>
<td>Reserpine</td>
<td>Inhibitor</td>
<td>ATP hydrolysis assay</td>
<td>Wang <em>et al.</em>, 2001</td>
</tr>
<tr>
<td><strong>Antiarrhythmics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Kakumoto <em>et al.</em>, 2002</td>
</tr>
<tr>
<td>Porafenone</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Woodland <em>et al.</em>, 1997</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Fromm <em>et al.</em>, 1999</td>
</tr>
<tr>
<td>Verapamil</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Pauli-Magnus <em>et al.</em>, 2000</td>
</tr>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Inducer</td>
<td>indinavir</td>
<td>Lin <em>et al.</em>, 1999</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrovastatin</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>boyd <em>et al.</em>, 2000</td>
</tr>
<tr>
<td>Bromocriptine</td>
<td>Inhibitor</td>
<td>vincristine</td>
<td>Orlowski <em>et al.</em>, 1998</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Verstuyft <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Emetine</td>
<td>Inhibitor</td>
<td>ATP hydrolysis assay</td>
<td>Wang <em>et al.</em>, 2001</td>
</tr>
<tr>
<td>Melfoquine</td>
<td>Inhibitor</td>
<td>vinblastine, fluo-3 acetomethoxy ester, rhodamine 123</td>
<td>Riffkin <em>et al.</em>, 1996</td>
</tr>
<tr>
<td>Progesterone</td>
<td>Inhibitor</td>
<td>vinblastine</td>
<td>Bernes <em>et al.</em>, 1996</td>
</tr>
<tr>
<td>Retinoic acid</td>
<td>Inducer</td>
<td>vinblastine, colchicine</td>
<td>Elhafny <em>et al.</em>, 1997</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Nakamura <em>et al.</em>, 2001</td>
</tr>
<tr>
<td><strong>Antiviral agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprenavir</td>
<td>Inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td>Inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>Inhibitor/Inducer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Reinhard <em>et al.</em>, 2004; Schmitt <em>et al</em>. 2010</td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Schmitt <em>et al</em>. 2010</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Wakasugi <em>et al.</em>, 1998</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Kim <em>et al.</em>, 1999</td>
</tr>
<tr>
<td>Rifampin</td>
<td>Inducer</td>
<td>digoxin</td>
<td>Greiner <em>et al.</em>, 2002</td>
</tr>
<tr>
<td><strong>Antimycotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraconazole</td>
<td>Inhibitor</td>
<td>vinblastine, daunorubicin, dauxorubicin</td>
<td>Takara <em>et al.</em>, 1999</td>
</tr>
<tr>
<td><strong>Immunosuppressants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Inhibitor</td>
<td>rhodamine 123</td>
<td>Takano <em>et al.</em>, 1998</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Inhibitor</td>
<td>rhodamine 123</td>
<td>Yacyshyn <em>et al.</em>, 1996</td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Minocha <em>et al.</em>, 2012</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Inhibitor</td>
<td>vincristine</td>
<td>Kochi <em>et al.</em>, 1999</td>
</tr>
<tr>
<td>Valspodar</td>
<td>Inhibitor</td>
<td>N-methyl-quinidine</td>
<td>PSC 833</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Inhibitor</td>
<td>digoxin</td>
<td>Parienteet <em>et al.</em>, 2009</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>Inhibitor</td>
<td>calcein-AM</td>
<td>Weiss <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Sertraline</td>
<td>Inhibitor</td>
<td>calcein-AM</td>
<td>Weiss <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Drug</td>
<td>Type</td>
<td>Interacting Drug</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
<td>------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>St John’s wort</td>
<td>Inducer</td>
<td>digoxin</td>
<td>Durr <em>et al.</em>, 2000</td>
</tr>
<tr>
<td>Neuroleptics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Inhibitor</td>
<td>verapamil</td>
<td>Saitoh and Aungst, 1995</td>
</tr>
<tr>
<td>Flupenthixol</td>
<td>Inhibitor</td>
<td>iodoarylazidoprazosin</td>
<td>Maki <em>et al.</em>, 2003</td>
</tr>
<tr>
<td>Phenothiazine</td>
<td>Inhibitor</td>
<td>vincristine</td>
<td>Watanabe <em>et al.</em>, 1995</td>
</tr>
<tr>
<td>Opioids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>Inhibitor</td>
<td>vinblastine</td>
<td>Callaghan and Riordan, 1993</td>
</tr>
<tr>
<td>Morphine</td>
<td>Inducer</td>
<td>expression</td>
<td>Aquilante <em>et al.</em>, 2000</td>
</tr>
<tr>
<td>Pentazocine</td>
<td>Inhibitor</td>
<td>vinblastine</td>
<td>Callaghan and Riordan, 1993</td>
</tr>
<tr>
<td>SNP</td>
<td>Drug</td>
<td>Parameter</td>
<td>Effect</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------</td>
<td>------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>C3435T (Exon 26)</td>
<td>Digoxin (oral, ss)</td>
<td>Drug level</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC(0-4 h), $C_{\text{max}}$</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC, $t_{\text{max}}$</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td>Fexofenadine</td>
<td>AUC</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Nelfinavir</td>
<td>Drug level</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td>Cyclosporine</td>
<td>Trough level</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AUC, $C_{\text{max}}$, $t_{\text{max}}$</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Cyclosporine</td>
<td>AUC(0-4 h)</td>
<td>Lower for CT/TT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level</td>
<td>Higher for TT/CT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Tacrolimus induced neurotoxicity</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Nortriptyline</td>
<td>Drug level</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Talinolol</td>
<td>AUC</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Loperamide</td>
<td>$C_{\text{max}}$, AUC, CNS effects</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Dicloxacillin</td>
<td>Drug level</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Docetaxel</td>
<td>Clearance</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Phenytoin</td>
<td>Drug level</td>
<td>Higher for TT</td>
</tr>
<tr>
<td>G2677T/A (Exon 21)</td>
<td>Digoxin (oral, sd)</td>
<td>AUC</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC(0-4h), $C_{\text{max}}$</td>
<td>No difference</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral, sd)</td>
<td>AUC, $t_{\text{max}}$</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td>Digoxin (oral-iv, sd)</td>
<td>Bioavailability</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Fexofenadine</td>
<td>AUC</td>
<td>Lower for TT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level</td>
<td>Higher for TT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level</td>
<td>Higher for TT/CT/GT</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td>Drug level, dose ratio</td>
<td>No difference</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Tacrolimus induced neurotoxicity</td>
<td>Higher for TT (trend)</td>
<td>Yamauchi et al., 2002</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Talinolol</td>
<td>AUC</td>
<td>Slightly higher for TA/TT</td>
<td>Siegmund et al., 2002</td>
</tr>
</tbody>
</table>

ss, steady state; sd, single dose
In recent decades, DDIs with selective P-gp inhibitors have been exploited to boost the efficacy of anticancer drugs. The idea was first introduced in 1981 when Tsuruo et al. discovered that verapamil increased the sensitivity of multi-drug resistant leukemia cells to chemotherapeutic drugs in vitro (90). As a consequence of this study, additional work has been put into designing potent and selective P-gp inhibitors to be used as adjuncts to chemotherapy. In one Phase I clinical study, there was an 89% increase in AUC and 46% decrease in clearance of etoposide in response to intravenous infusion of the selective P-gp inhibitor PSC-833 (91). Today, P-gp inhibitors may also be applied to enhancing drug penetration through the blood-brain-, blood-cerebrospinal-, and maternal-fetal-barriers as well (92-94).

Beyond DDIs, different polymorphisms of the MDR1 gene exist in the population with varied functional consequences (Table 1.3). Kioka et al. were the first to identify MDR1 polymorphisms in 1989 from in vitro study of cancer cells; since that time over 2 dozen MDR1 SNPs have been reported with different frequencies across ethnic populations (95-98). A cytosine to thymine SNP at position 3435 in exon 26 (C3435T) was the first polymorphism reported to affect P-gp protein expression, although this SNP does not alter the encoded amino acid – thus referred to as a synonymous SNP (99). Healthy Caucasian subjects with the variant T allele were shown to have a 2-fold reduction in duodenal P-gp expression as compared to subjects with the wild type C allele (99). These individuals also showed increased plasma concentration of the P-gp probe substrate digoxin following its oral administration; this suggesting enhanced oral absorption in individuals with diminished duodenal P-gp expression. Several different studies confirmed the impact of this polymorphism (100-102). But others have actually reported the variant allele (3435T) to yield decreased serum digoxin (103; 104), or to have no clinical effect at all (105). As with DDIs, the clinical impact of P-gp polymorphisms can be quite ambiguous and complex.
1.2.2.6 Relevance to drug development

Owing to improvements in CYP molecular biology, to readily available *in vitro* models, and to in silico approaches, high-throughput scanning of CYP enzymes has been increasingly embraced by industry and regulatory agencies for almost 2 decades (106-108). As the body of work in the area of drug transporters catches up with DMEs and the role of drug transport in clinical PK is further elucidated, pre-clinical assessment of transporter interactions has become an area of growing interest in drug discovery and development (109-111). An early understanding of P-gp in drug pharmacokinetics facilitates the recognition of important clinical DDIs and polymorphisms that may greatly impact the disposition, dosing regimens, therapeutic efficacy and safety of a great number of drugs and drug candidates (112; 12). Current FDA guidance describes experimental systems, experimental designs and decision criteria to assess new chemical entities (NCEs) and drug candidates for P-gp interactions (113). Compounds that demonstrate significant interaction with P-gp, based on up-to-date *in vitro* and/or *in vivo* testing, may be required to undergo additional studies to demonstrate safety and optimal use, or may even be withdrawn in extreme cases. Study of P-gp is an integral component of pre-market drug development and regulatory review (12; 114; 115) and P-gp testing is typically carried out, like other PK tests, in parallel to pharmacodynamic studies of drug response (116). P-gp tests are especially important for drugs that are intended for oral administration, or are targeted to the CNS. Furthermore, as part of post market drug monitoring, P-gp interaction studies have elucidated the mechanisms of several reported drug-drug interactions, population variations, or rare adverse drug events.

1.2.2.7 Animal models

Shortly after the physiological expression of P-glycoprotein in human tissues became apparent in the late 80s, P-gp was also found to be expressed in the isolated brain capillaries of mice, rats, pigs and cows (117-120). Various forms of P-gp have also been reported to express in numerous other species of insects, fish, amphibians, reptiles, birds, and mammals. Today, closely related homologues of *ABCB1* have been cloned and sequenced in human, mouse, Chinese hamster, dog and other species including, Caenorhabditis elegans and Drosophila melanogaster (121; 122). In higher mammals P-
gp forms a small gene family, with only one drug transporting isoform expressed in humans (MDR1/ABCB1), and two co-operative drug transporter isoforms expressed in rodents (mdr1/ABCB1a and mdr3/ABCB1b) (123-125).

Recent advancements in transgenic animal models and knock out animals allow us to study the in vivo role of specific ADME proteins in human PK and drug-drug interactions. For instance, single and double P-gp knockout mouse models, lacking ABCB1a and ABCB1b, have been bred for in vivo pharmacokinetic studies. While these mice do show increased sensitivity to drug and xenobiotic exposure, they are viable and fertile for study (126). Moreover, although compensatory upregulation of complimentary enzymes or transporters may somewhat disguise the absence of P-gp in the mice (127), P-gp-deficient animal models provide valuable information about weather a drug is a substrate or modulator of MDR1 (128-130). As well, these particular knockout models have proven very useful in assessment of the impact of P-gp on the CNS penetration of psycho-active drugs. For example, Schinkel et al. compared the disposition of the veterinary pesticide ivermectin in knockout mice against wild type mice (57; 131). They saw a 100-fold greater brain ivermectin AUC in mdr1a (-/-) mice as compared to wild type. The increased brain exposure in the knockout mice resulted in a much greater neurotoxicity and mortality in the knockout mice versus the wild type mice that had regular expression of blood-brain-barrier P-glycoprotein.

Of note, caution must be taken when extrapolating the pharmacokinetics in an animal model to the human situation. Scaling animal pharmacokinetics solely by weight (allometric scaling) is not always effective due to species differences in a variety of physiological and biochemical properties, including organ blood perfusion, pH, gastric emptying time and various other factors. Moreover, species differences in the expression, localization, regulation and substrate specificity of DMEs and drug transporters can yield significantly different pharmacokinetics for a drug in humans versus an animal model. Early studies looked at the resistance profiles of Chinese hamster ovary cells overexpressing human MDR1 and murine mdr1 and mdr3 genes; the resistance conferred by MDR1 versus mdr1/3 was significantly different for various MDR drugs, as was the effect of different P-gp modulators on vinblastine resistance (132). A variety of
subsequent studies further confirmed species differences for several different P-gp substrates and modulators (50; 133-135). Although transgenic animal models expressing humanized proteins are currently available to improve the accuracy of human extrapolation, most are created for human drug metabolizing enzymes.

1.3 **In vitro to in vivo (IVIV) prediction of pharmacokinetics**

1.3.1 General scheme

Various transporter and DME interactions and DDIs have led to prescribing restrictions, market withdrawals, new drug submission rejections and early development terminations, for many pharmaceutical agents (136). So, it’s not surprising that regulatory bodies, including the FDA and the European Medicines Agency (EMA), as well as academics are increasingly concerned about the contributions of key DMEs and transporters to drug disposition. *In vitro to in vivo* extrapolation (IVIVE) allows us to characterize the activity of ADME proteins *in vitro*, so as to clarify and predict their roles in the *in vivo* kinetics of drugs and drug candidates. It helps us to explain and predict the bioavailability, clearance and tissue distributions of clinically important drugs. For example, a compound that is identified *in vitro* as a strong P-gp substrate will likely show a high level of P-gp efflux *in vivo*. One *in vivo* consequence of compounds with efficient efflux by P-gp would be a significant decrease in oral absorption of the compound, since P-gp is highly expressed in the intestinal lumen where it actively opposes the absorption of substrate compounds. Characterizing drug-transporter and drug-enzyme interactions through *in vitro* studies is an essential step in understanding drug PK or in anticipating whether or not a drug is likely to exhibit favourable clinical PK. Certainly, important early decisions in drug discovery and development (DDD) are based on the interpretation of preclinical *in vitro* studies and their implications to *in vivo* kinetics (116; 137; 136).

1.3.2 Quantitative IVIVE

For quantitative IVIVE, additional information is required about the ADME protein and about the *in vitro* and *in vivo* systems that are being compared (Figure 1.1).

The rate of metabolism for a given enzyme-substrate pair in any *in vitro* or *in vivo* system, is proportional both to the absolute intrinsic activity of that enzyme on its
substrate and to the total amount of that enzyme expressed in the given system. Likewise, the rate of carrier-mediated transport for a given transporter-substrate pair in a system, is proportional to the absolute intrinsic activity and amount of that transporter in the system (138). Absolute intrinsic activity describes the characteristic efficiency at which an individual enzyme or transporter turns over substrate. It is a system-independent, inherent biochemical property of each individual ADME protein and is thus consistent, for a given protein, across in vitro and in vivo systems. So, it follows that quantitative in vitro to in vivo extrapolation is accomplished by scaling the amount of enzyme and/or transporter between systems, with a constant absolute intrinsic activity. Absolute intrinsic activity can be determined from the in vitro intrinsic activity in a system of known enzyme/transporter amount. In order to quantify transporter/enzyme amount, functional units of a system, such as cell number or protein content, are often used as convenient surrogates for actual transporter/enzyme content.

More sophisticated IVIVE models include information about the in vivo relative abundances of interacting enzymes and transporters, along with physiological parameters that dictate enzyme or transporter access to unbound drug (e.g. tissue perfusion rates, solubility etc.). Physiologically-based pharmacokinetic (PBPK) models have been developed in the past decades to integrate quantitative description of various simultaneous and dynamic physiological and pharmacokinetic processes, arranged within a structural framework that represents the anatomical arrangement of the body. These models have enjoyed increasing popularity in recent years for their ability to compile and contextualize a wealth of available in vitro and in vivo data. PBPK models have proven most useful in the prediction of DDIs, population PK and toxin exposure (139-142).
**Figure 1.1.** Simplified general scheme of quantitative IVIVE for hepatically eliminated drugs. Models are organized as tissue and extracellular compartments (e.g. Liver, hepatic sinusoids, hepatic canaliculi) perfused by blood flow (Q). Movement of unbound drug into and out of compartments is defined by physiologically relevant, drug-specific clearance parameters ($CL_{\text{metabolism}}$, $CL_{\text{transport}}$) that relate to ADME protein activities. The clearance parameters are estimated from information about ADME protein expression in *in vivo* human tissues; and from information about *in vitro* ADME protein intrinsic clearance, normalized to *in vitro* protein expression. All clearance and flow parameters interplay dynamically with each other and have differing relative contribution to the overall PK of a given drug.
1.3.2.1 Intrinsic clearance in PK modeling

Intrinsic clearance (CL\textsubscript{int}), a term first coined in 1975 by Wilkinson and Shand, describes the perfusion-rate-independent clearance of a drug from a system by the cumulative intrinsic activities of the contributing drug metabolizing enzymes and/or transporters. It is a cardinal PK parameter in quantitative IVIVE and PBPK modeling. Indeed, scaling of the intrinsic clearance of \textit{in vitro} expressed liver enzymes and transporters has shown to be a robust method of predicting \textit{in vivo} hepatic drug clearance (143-147). Intrinsic metabolic clearance (CL\textsubscript{int} or CL\textsubscript{int(Metabolism)}) was first described, for hepatic enzyme kinetics in an isolated hepatocyte \textit{in vitro} system, as the initial metabolic activity (V\textsubscript{0}) in the hepatocytes proportional to the concentration of free drug (C\textsubscript{u}) available to the hepatocytes for metabolism,

\[
\text{CL}_{\text{int}} = \frac{V_0}{C_u}
\]  \[1.5\]

Substituting this into the Michaelis-Menten equation for enzyme kinetics (described in section 1.3.2.2),

\[
v = \frac{V_{\text{max}}C_u}{K_m+C_u}
\]  \[1.6\]

gives the following relationship:

\[
\text{CL}_{\text{int}} = \frac{V_{\text{max}}}{K_m+C_u}
\]  \[1.7\]

So, at low substrate concentration (C\textsubscript{u} \ll K\textsubscript{m}), intrinsic clearance is proportional to V\textsubscript{max}, inversely proportional to K\textsubscript{m} and independent of substrate concentration; expressed as,

\[
\text{CL}_{\text{int}} = \frac{V_{\text{max}}}{K_m}
\]  \[1.8\]

The situations in equations [1.5-1.8] can all be applied analogously to describe the intrinsic transporter-mediated clearance (CL\textsubscript{int} or CL\textsubscript{int(Transport)}) of any drug from a given compartment. This could be, for instance, applied to describe the \textit{in vitro} carrier-mediated uptake of a drug into cultured cells in suspension, or applied to describe the \textit{in vivo} secretion of a drug from the liver into the bile.
Along with $\text{CL}_{\text{int(Metabolism)}}$ and $\text{CL}_{\text{int(Transport)}}$, several other physiological parameters (e.g. blood flow, tissue perfusion) and drug-specific parameters relating to the free drug concentrations (e.g. plasma protein binding, tissue binding), chemical disposition, chemical dispersion, and availability for clearance, all factor into determination of the true *in vivo* clearance. The so-called “well-stirred” model description for hepatic metabolic clearance (148) provides a simple example:

$$\text{CL}_{\text{Total Liver}} = \frac{Q_L \cdot f_u \cdot \text{CL}_{\text{int}}}{Q_L \cdot f_u \cdot \text{CL}_{\text{int}}}$$

[1.9]

where, $Q_L$ is the physiological blood flow to the liver, $f_u$ is the fraction of drug in the blood that is unbound and available for metabolism, and $\text{CL}_{\text{int}}$ is the overall intrinsic metabolic clearance of the liver (scaled up from *in vitro* isolated hepatocytes). The $\text{CL}_{\text{int}}$ rate in this model may define the intrinsic activity of one enzyme or, depending on the drug, it could incorporate the intrinsic activities of a collection of hepatic enzymes that all contribute to the elimination of a common substrate drug. Note though, that there is no term for intrinsic carrier-mediated clearance in equation [1.9]; this simplified case describes a metabolic clearance that is rate-limited by hepatic blood perfusion, in which unbound drug in the blood bathing the liver establishes instantaneous equilibrium with the hepatocytes by rapid passive diffusion, such that the intrahepatic and extrahepatic concentrations of free drug are viewed to be equal. Thus, as unbound drug perfuses the liver it is immediately available for metabolism at a rate, $\text{CL}_{\text{int}}$, that is intrinsic to the liver enzymes and any active transport is assumed to be negligible. In reality, for many drugs that display lower passive permeability, carrier-mediated transport into the liver (uptake) or into the bile (efflux) may rate-limit *in vivo* liver clearance (149; 150). Kinetic models that fail to account for important active uptake and/or efflux processes can result in an under- or over-estimation of system intrinsic clearance parameters (151).

Successful quantitative IVIVE of drug clearance requires proper integration of the multiple dynamic PK processes of different relative importances. A model of the *in vivo* hepatic clearance of enalapril in rats, by Sirianni and Pang (Figure 1.2) (152), demonstrates some of the interplay between transport and metabolism:
Figure 1.2. Schematic depiction of the physiological model for liver clearance. The liver is divided into three compartments: the reservoir ($R$, or systemic blood compartment), liver plasma ($PL$), and liver tissue ($L$). $Q$, $C$, and $V$ represent flow, concentration, and volume, respectively. The transport clearances for drug from hepatic plasma to tissue and from tissue to hepatic plasma are characterized by influx ($CL_{influx}$) and efflux ($CL_{efflux}$) clearances, respectively. Drug metabolism within the liver tissue is characterized by the intrinsic clearance, $CL_{int,met}$. Biliary excretion of drug is characterized by the intrinsic clearance, $CL_{int,sec}$. Modified from Sirianni and Pang, 1997.
\[ CL_{Total\ Liver} = \frac{Q_L \times f_u \times CL_{influx}(CL_{int,met}+CL_{int,sec})}{Q_L(CL_{efflux}+CL_{int,met}+CL_{int,sec})+f_u CL_{influx}(CL_{int,sec}+CL_{int,met})} \]  [1.10]

where, \( Q_L \) is the blood flow to the liver, \( f_u \) is the fraction of drug in the blood that is unbound and available for metabolism, \( CL_{int,met} \) is the intrinsic metabolic clearance, \( CL_{influx} \) and \( CL_{efflux} \) are respectively the intrinsic influx and intrinsic efflux at the sinusoidal membrane, and \( CL_{int,sec} \) is the secretory intrinsic efflux at the canalicular membrane. \( CL_{Total\ Liver} \) in the rat is solved for by writing mass balance equations for the reservoir, liver plasma, liver tissue, and bile compartments. In order to find agreement between model simulations and \textit{in vivo} rat data sets, the \textit{in vivo} relationships between many of the interacting parameters had to be defined. For example, since \( CL_{influx} \) and \( CL_{int,met} \) simultaneously contribute to the tissue compartment drug level, Liu and Pang defined the \( CL_{influx}/CL_{int,met} \) ratio as 6.56, based on the \( V_{max} \) and \( K_m \) kinetics observed for enalapril uptake and metabolism that were previously observed in homogenous isolated rat hepatocyte studies (152-154).

As a greater amount of kinetic information about transporter and enzyme intrinsic clearances, along with other physiological information, becomes available for different drugs, the precision of more detailed physiologically-based models can continually improve. Indeed, there has been continued development in dynamic models for intestinal absorption and BBB permeability in recent years as well (155-158).

1.3.2.2 Facilitated (Carrier-mediated) transport kinetics

Carrier-mediated transport of substrate across a membrane is characterized by saturability and it can be described analogously with the Michaelis-Menten equation for enzyme kinetics,

\[ v = \frac{V_{max}C}{K_m+C} \]  [1.6]

where \( v \) is the rate of carrier-mediated transport; \( V_{max} \) is the maximum rate of carrier-mediated transport; \( C \) is the substrate concentration; and \( K_m \) is the Michaelis constant, calculated as the substrate concentration at half of \( V_{max} \). When \( C \) is much smaller than \( K_m \), the rate of transport, \( v \), shows a linear proportionality with substrate concentration. However, as \( C \) gets large compared to \( K_m \) the rate of transport no longer increases in
proportion to C, and \( v \) plateaus at a constant value \( (V_{\text{max}}) \). At \( V_{\text{max}} \), transport is saturated and \( v \) is limited by the rate at which transporters turn over substrate and by the density of transporters on the plasma membrane. To determine \( V_{\text{max}} \) and \( K_m \) \textit{in vitro}, transport is measured over a time course and over a range of drug concentrations. The Michaelis constant is a substrate-dependent parameter that relates to the affinity of a given transporter for a specific substrate.

The Michaelis-Menten equation was originally developed for soluble enzymes, which bind their substrates directly from the aqueous phase. Application of this equation to the kinetics of transport assumes that the equation parameters correlate reasonably well with the association and dissociation elementary rate constants of the substrate, transporter, and substrate-transporter complex (159). This is a reasonable approximation for drug transporters that bind their substrates directly from the aqueous phase and/or for the ATPase activity that occurs in the aqueous phase for ABC transporters (160). Thus, while the Michaelis-Menten parameters may not directly describe the discrete physical processes of drug transport, they still offer a useful estimate of transporter activity and good predictive value.

1.3.3 \textit{In vitro} systems for estimating metabolism and transport

1.3.3.1 Hepatocytes, recombinant cells, and membrane vesicles

Drug metabolizing enzyme activity is estimated \textit{in vitro}, often as an \textit{in vitro} intrinsic metabolic clearance using equation [1.7], by incubating a drug substrate in an appropriate \textit{in vitro} system and measuring metabolite formation or substrate disappearance over a range of concentrations. Currently, isolated human hepatocytes in suspension are the most practical \textit{in vitro} system for metabolism studies to predict whole organ drug clearance (161; 138; 162). Microsomal fractions and recombinant enzyme systems may be used for more specific testing of particular enzymes of interest. Routine studies are recommended by the FDA to characterize the interactions of compounds with the following enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A (113).
Freshly isolated cryopreserved hepatocytes can also be used to study hepatic uptake transporters *in vitro* (162; 163). The common approach is to incubate substrate with a suspension of hepatocytes and measure drug accumulation in the cell after a period of time. Typically accumulation is measured over a range of concentrations to demonstrate saturable active transport kinetics. These active transport studies yield Michaelis-Menten kinetic parameters for carrier-mediated transport:

$$V = \left( \frac{V_{\text{max}} \times C}{K_m + C} \right) + (P_{\text{diff}} \times C)$$  \[1.11\]

Where $V$ is the rate of carrier-mediated transport, $V_{\text{max}}$ is the maximum rate of carrier-mediated uptake, $K_m$ is the Michaelis constant, $C$ is the drug concentration, and $P_{\text{diff}}$ is the non-carrier-mediated passive clearance. Addition of the $P_{\text{diff}} \times C$ product to the usual Michaelis-Menten equation for active transport is necessary to account for the component of *in vitro* transport rate into the cell that is due to passive, non-carrier-mediated transport.

Application of Michaelis-Menten kinetics to *in vitro* carrier-mediated transport studies often operates under the assumption that only one type of transporter is responsible for transport in the system. Significant contribution by other transporters with overlapping substrate specificity can obscure the activity of the transporter of interest and interfere with the estimation of its kinetics. In the case of fresh hepatocytes, a variety of different transporter families are in fact expressed that may contribute to transport of various drug substrates. Also, cryopreserved hepatocytes cannot be used to study efflux transporters because the process of hepatocyte isolation causes canalicular efflux transporters to be internalized (164; 165). As well, none of the *in vitro* studies done in hepatocytes are appropriate for the study of transporters that are not expressed in the liver, including organic cation transporter 2 (OCT2) and organic anion transporter 1 and 3 (OAT1 and 3) proteins, which localize to the kidney. Recombinant cells can be used to better isolate the activity of any individual uptake transporter on a drug of interest.

An important distinction must be made before attempting to apply the models described above to the *in vitro* study of drug efflux transporters. Uptake transporters bind substrate
from the extracellular environment, where measurement and manipulation of drug concentrations is technically achieved very easily in a suspension or permeable-support system. Efflux transporters, on the other hand, extrude substrate from the intracellular space, which is largely inaccessible in these experimental systems. As such, more sophisticated \textit{in vitro} strategies must be employed in determining the kinetics of efflux transport.

The ATPase, calcein-AM fluorescence, and rhodamine-123 fluorescence assays all circumvent the issue of intracellular inaccessibility by using indirect measures of substrate transport. The ATPase assay estimates the activity of ABC efflux transporters, by measuring the ATP hydrolysis that is coupled to their transport activity. Calcein-AM and rhodamine-123 fluorescence cell assays are designed specifically to evaluate \textit{ABCB1} (P-gp) or \textit{ABCC1} (Multidrug resistance-associated protein 1, MRP1) efflux transporter activity. Non-fluorescent calcein-AM or non-fluorescent rhodamine-123 diffuses into cells where it is hydrolyzed by intracellular esterases into a fluorescent compound, which accumulates intracellularly. Membrane P-gp and MRP1, however, opposes the inward diffusion of these non-fluorescent compounds into the cells. Consequently, drugs that interact with P-gp or MRP1 can affect efflux transporter activity, resulting in a measureable change in the rate of accumulation of intracellular fluorescent compound. (166; 167) Each of these indirect assays offers a high throughput analysis of potential substrates that is readily automated. But, the ATPase, calcein-AM fluorescence, and rhodamine-123 fluorescence assays are not able to distinguish efflux transporter substrates from inhibitors (167-169).

Alternatively, other strategies allow direct measurement of efflux transporter activity; the inverted membrane vesicle assay is one such strategy. Transporter-expressing plasma membrane vesicles are inverted, such that the efflux transporters bind and actively pump substrate from the external environment into the closed vesicle. This orientation permits easy manipulation and measurement of the donor drug concentrations that is seen by the efflux transporters. In this orientation transporter kinetics can be evaluated just as they would be for an uptake transporter. However, compounds with moderate-to-high passive permeability leak back out of the vesicle after being pumped in and thus may be falsely
labeled as non-substrates by the inverted membrane vesicle assay. Moreover, the relative orientation of efflux transporters, they being inside-out or outside-in facing, will impact the effectiveness and interpretation of transport kinetics.

1.3.3.2 The cell monolayer permeability assay for efflux transport

The cell monolayer permeability assay is also designed to measure efflux transport activity in a direct fashion and it is the gold standard used in industry (Figure 1.4). The assay estimates efflux transporter activity by assessing permeability – comprised of both passive diffusion and active transport – across a monolayer composed of an immortalized cell line. The monolayer cells either have innate polarized efflux transporter expression, or are transfected to stably or transiently express polarized recombinant efflux transporter. A “transwell” set up is employed, where the monolayer is grown on a semipermeable insert, which is set into a well. This set up creates one accessible compartment on each side of the cell monolayer; commonly, as determined by cell polarization in culture, the top compartment is apical and the bottom is basolateral. Then, in order to estimate apical efflux transporter activity, which pumps drug away from the basolateral compartment and towards the apical compartment, drug is added to either side of the monolayer (the donor compartment) and its appearance on the opposing side (the receiver compartment) is measured. Efflux transporter activity is reflected in the degree of drug movement from donor to receiver compartments.

Like the inverted membrane vesicle assay, monolayer permeability assays may also fail to identify the efflux transport of some highly permeable drugs, but carrier-mediated efflux is unlikely to pose a significant barrier to the in vivo absorption of highly permeable drugs. Another limitation of this model is its inability to directly measure intracellular drug concentrations, which is the level that actually drives the rate of apical efflux transporters. For convenience, the intracellular concentration is often assumed to be in rapid equilibrium with the drug concentration measured in the basolateral compartment, which can be easily manipulated. In this way the system can be viewed as a single apical efflux barrier between two testable compartments: the basolateral/intracellular compartment and the apical compartment. In reality however, the intracellular concentration can vary significantly from the basolateral compartment.
Figure 1.3. The cell monolayer permeability assay. A polarized monolayer of cells with apical P-gp expression. $P_{app}$ is calculated in both directions from drug flux into the receiver compartment following apical or basolateral administration.
depending on the presence of unaccounted for basolateral uptake processes, which may
differ between the monolayer cell lines used and/or between laboratory culture conditions
(170-174). As previously mentioned, the presence of unaccounted for transporters can
obscure accurate determination of the activity and kinetics of a transporter of interest.

1.3.4 In vitro estimation of drug efflux activity in the monolayer permeability
assay

Various calculations have been proposed to estimate efflux transporter activity from a
monolayer permeability assay.

1.3.4.1 Directional apparent permeability

Since the presence of P-gp or other unidirectional apical efflux transporters can both
enhance basolateral to apical flux and attenuate apical to basolateral flux of a substrate
drug, efflux transporter activity can be assessed from the permeability in either direction.
Both increased basolateral to apical apparent permeability ($P_{\text{app}}(B-A)$) and decreased apical
to basolateral apparent permeability ($P_{\text{app}}(A-B)$) are used to identify a compound as a
substrate for efflux transport.

The apparent permeability ($P_{\text{app}}$) of a compound in one direction across the monolayer is
estimated from the rate of appearance of drug in the receiver compartment measured
during an incubation time. It is given by the following equation,

$$P_{\text{app}} = \frac{(dA_R/dt)/(S\times C_{D,0})}{[1.12]}$$

Where $P_{\text{app}}$ is the apparent permeability in distance per unit time, $dA_R/dt$ is the cumulative
amount of compound appearing in the receiver compartment with respect to incubation
time, $S$ is the surface area across which transport occurs, and $C_{D,0}$ is the initial
concentration administered to the donor compartment. For $P_{\text{app}}(B-A)$, $dA_R/dt$ specifies the
rate at which drug appears in the apical compartment and $C_{D,0}$ is the initial concentration
added in the basolateral compartment. Oppositely, for $P_{\text{app}}(A-B)$, $dA_R/dt$ specifies the rate
at which drug appears in the basolateral compartment and $C_{D,0}$ is the donor concentration
added in the apical compartment.
1.3.4.2 Efflux ratio

Efflux ratio (EfR), the ratio of $P_{app(B-A)}$ to $P_{app(A-B)}$, is also used to evaluate efflux transporter activity. It relates the relative permeabilities in both directions across the monolayer, demonstrated by the relationship in Equation 1.13,

$$\text{EfR} = \frac{P_{app(B-A)}}{P_{app(A-B)}}$$  \[1.13\]

Where EfR is the efflux ratio, $P_{app(B-A)}$ is the basolateral to apical permeability of the drug across the cell monolayer and $P_{app(A-B)}$ is the apical to basolateral permeability. A drug that does not experience any active efflux would have an EfR equal to 1. Conversely, a substrate for apical efflux transport would show increased EfR (value > 1), demonstrating asymmetric basolateral to apical permeability.

1.3.4.3 Modeled intrinsic transport clearance

Efflux transporter activity can also be estimated from a cell monolayer permeability assay as a modeled intrinsic transporter clearance ($CL_{\text{int(Transport)}}$). Cellular kinetic models of varying complexity have been designed to describe drug movement between compartments of a transwell system, with respect to time (171; 172; 176-178). The drug concentrations, which are experimentally measured from the donor and receiver compartments throughout the drug incubation period, can be used as inputs for mathematical models to derive parameter values for the dynamic kinetic processes of the transwell. The intrinsic efflux clearance ($CL_{\text{int(Efflux)}}$ or $CL_{\text{int}}$), as it is defined in any given model, provides a direct quantitative estimate of the activity of efflux transporters on an in vitro test drug. This is different than $P_{app}$ and EfR, which only qualitatively estimate efflux transporter kinetics. Also unlike $P_{app}$ and EfR, this modeled approach isolates and quantifies the activity of the efflux transporter of interest. Take for example, the compartmental model applied by Tam et al. (Figure 1.4); this model was able to examine specifically the effect of P-gp efflux transport on drug metabolism in cytochrome P450 expressing Caco-2 cell intestinal models (173).

Since the modeled clearance approach isolates the activity of a given transporter, it should also be more easily relatable across the various cell lines that are commonly used.
**Figure 1.4.** Compartment model for drug transport in a Transwell experimental system. Permeation of drug (D) from the apical compartment into the cell compartment, whether mediated by uptake transporters or passive diffusion, is associated with the absorption rate constant, $k_a$; secretion (efflux) from the cell back into the apical compartment occurs with the intrinsic clearance, $CL_{int,sec}$. Drug partitioning between the cell and the basolateral compartment is mediated by influx and efflux clearances, $CL_{d1}$ and $CL_{d2}$, respectively, as shown. Drug binding to proteins present in the apical compartment due to sloughed off mucosal cells (unbound fraction $f_{ap}$), within the cell (unbound fraction $f_{cell}$), and in the basolateral compartment (unbound fraction $f_{baso}$) affects the transfer and metabolic rates based on unbound drug concentrations. The rate of total metabolite formed, under first-order conditions, is given by $f_{cell}D_{cell}CL_{int,met}/V_{cell}$, where $D_{cell}$ is the amount of drug within the cellular compartment of volume, $V_{cell}$. Modified from Tam et al., 2003.
for monolayer permeability assays. Modeled clearance can account for uptake transport parameters as well as other passive and active transport processes that may be specific to different cell lines or culture conditions. In this way, modeled $CL_{int}$ should be transfereable between systems, whereas $P_{app}$ and $EfR$ values derived from different systems may not relate well. $CL_{int}$ is thus likely more useful for extrapolating the efflux transport activity of a particular transporter in question.

1.3.5 **Current recommendations for in vitro assessment of efflux transporter activity**

Some of the most important considerations for constructing a successful *in vitro* study with good *in vivo* predictive value are: the selected test system, analysis of experimental data, and the chosen test drug.

Of the available *in vitro* techniques, monolayer permeability assays are recommended for *in vitro* assessment of efflux transporter activity (17; 179-183). More specifically, colorectal adenocarcinoma (Caco-2) cells have been commonly used in industry and academia for study of P-gp efflux transporter interaction and used as a general *in vitro* model of intestinal absorption (184-187). Caco-2 cells are a continuous cell of heterogeneous human epithelial colorectal adenocarcinoma cells, which shows high level of endogenous P-gp expression on the apical membrane. In culture they take on morphological and biochemical characteristics very similar to those of the human intestinal epithelium, forming a confluent monolayer with tight junctions and a brush border membrane. Data from Caco-2 cell assays has been shown to correlate well with the *in vivo* absorption of orally administered drugs in man (188).

Notably, Caco-2 cells also show polarized expression of a variety of uptake and efflux transporters. Many of these transporters share overlapping substrate specificities with P-gp and have the potential to contribute to the transport kinetics of P-gp substrates. In addition to P-glycoprotein, Caco-2 cells express significant levels of breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 2 (MRP2) efflux transporters (189; 190) and fair levels of other transporters as well (Figure 1.5) (191-195).
Figure 1.5. Some of the putative transporter proteins expressed in cultured Caco-2 cells, including: apical BCRP, MRP2, MDR1, HPT1 (human peptide transporter 1), PepT1 (peptide transporter 1), and OATP2B1 (organic anion-transporting polypeptide 2B1), and basolateral MRP3, MRP1, and OST-α/β (organic solute transporter-α/β).
Madin-Darby canine kidney (MDCK) cells and porcine kidney (LLCPK) cells can be transfected with *MDR1* and so are often used to form a polarized confluent monolayer *in vitro* as an alternative to Caco-2 cells. The MDCK-MDR1 (MDCK cells stably transfected with *MDR1*) and LMDR1 (LLCPK cells stably transfected with *MDR1*) cells boast a shorter culture period and greater inter-passage homogeneity (182; 98). Also, when transfected with *MDR1* these cell lines typically overexpress P-gp at levels greater than endogenous Caco-2 cell expression. Nonetheless, LLCPK and MDCK cells have also been reported to show some native expression of other transporters and enzymes, including fairly prominent canine P-gp expression in MDCK cells (196).

In terms of data analysis, some monolayer permeability studies report using unidirectional apparent permeability for the evaluation of efflux transporter activity and classification of P-gp substrates and modulators (197). However, efflux ratio is commonly used in many other studies (179). Digoxin is also viewed as the ideal substrate for the investigation of P-gp DDIs (113), and it will be discussed in detail in Section 1.4.

### 1.4 Digoxin

#### 1.4.1 Historical perspectives

The cardiac glycosides are a group of chemically similar compounds that are often referred to as digitalis or digitalis glycosides because most are derived from the digitalis (foxglove) plant. The plant is native to western and south-western Europe, north-western Africa, western and central Asia and Australasia. In 1785 physician William Withering provided the first English language report of the use of cardiac glycoside-containing digitalis extract in the treatment of heart conditions. Cardiac glycosides are now known to inhibit the NA⁺/K⁺-ATPase pump in myocardial and smooth muscle cells. This creates an increased intracellular sodium concentration, which induces elevated intracellular calcium by means of the Na⁺/Ca²⁺ exchanger. The end result is increased contractility of the heart through a positive inotropic effect. Typical cardiac glycosides function by the same mechanism of action, but vary in their potency and pharmacokinetics.

The first digoxin product was brought to the American market in 1934 by Wellcome Chemical Works (now GlaxoSmithKline) at a time when the FDA had limited power to
regulate pharmaceuticals. As federal legislation evolved the FDA was empowered to impose more stringent safety and efficacy tests on all pharmaceuticals, including those already on the market. This resulted in several recalls of digoxin and eventually its resubmission as a new drug. The secondary glycoside digoxin (Lanoxin) was ultimately approved by the FDA in 1998 for heart failure, on the basis of the Digitalis Investigators Group (DIG), Randomized Assessment of Digoxin on Inhibitors of the Angiotensin Converting Enzyme (RADIANCE), and Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin (PROVED) clinical trials (198; 199; 200). Today digoxin is the cardiac glycoside most commonly used in North America.

1.4.2 Indications and use in Canada

Current Heart Failure Society of America (AHA)/American College of Cardiology (ACC) joint guidelines and Heart Failure Society of America (HSFA) guidelines recommend digoxin use for the treatment of symptomatic chronic heart failure with reduced or preserved systolic function and for ventricular rate control in atrial fibrillation (201; 202). At present, digoxin is the only effective oral inotropic agent available for treatment of chronic severe left systolic dysfunction (198; 203). Judicious use may also be warranted in cases of renal hypokalemia, renal impairment, hypomagnesemia, and hypothyroidism. When necessary, digoxin may also be carefully used in patients who suffer acute myocardial infarction with ongoing ischemia or electrical cardioversion.

The therapeutic concentration of digoxin for most heart failure patients is between 0.5 and 1.0 ng/mL from a daily dose of 0.125 to 0.25 mg/day. Close drug monitoring is especially imperative for digoxin because it has a very narrow therapeutic window, which means that the concentration at which toxic effects appear (≥ 2 ng/mL) is not substantially greater than therapeutic concentration. Early signs of digoxin toxicity are central nervous systems effects including dizziness, visual disturbance and nausea. Major digoxin toxicity is in large part a consequence of intracellular potassium depletion.

Digoxin is an affordable drug that, if properly monitored, can be used safely and effectively in conjunction with other heart failure drugs. Importantly though, co-administration of digoxin with intravenous calcium can precipitate potentially fatal
arrhythmias. Digoxin should also be avoided in patients with sinus node disease, second- or third-degree atrioventricular block, accessory atrioventricular pathways, hypertrophic cardiomyopathy, and cardiac amyloidosis. As well, physicians must be aware of the potential for drug-drug interactions, particularly those mediated by P-glycoprotein.

1.4.3 Clinical pharmacology

Drug-drug interactions are a real concern because of their potential to push serum digoxin concentrations outside of the narrow therapeutic window. Several clinically significant DDIs involving digoxin have been previously reported (181). One of the most studied is between digoxin and quinidine; first reported in 1968. Several prospective studies independently confirmed the interaction, reporting 2- to 3-fold increase in digoxin concentrations following concomitant quinidine administration (204; 205). This was demonstrated to be a result of increased oral bioavailability by quinidine inhibition of intestinal P-gp (206) and reduced renal clearance by inhibition of renal P-gp (207). Likewise, concomitant administrations of cyclosporine, quinidine, amiodarone, dronedarone, and valspodar with digoxin have all been reported to increase digoxin plasma concentrations by competing for P-gp transport or protein binding (208-212). Foods and other natural products have been shown to significantly affect digoxin pharmacokinetics as well. For instance, several studies with St John’s Wort have demonstrated decreased digoxin AUC resulting from induction of P-gp activity (213-216).

1.4.4 Discovery as a P-gp substrate

Evidently, many digoxin DDIs are mediated by P-glycoprotein. The first in vitro evidence for digoxin as a P-gp substrate came in 1992 from a study by de Lannoy and Silverman in Canada and from a study in the same year by Tanigawara et al. in Japan. Tanigawara’s group showed greater basolateral to apical transport of digoxin across an epithelial monolayer of polarized LMDR1 cells. The directionality was diminished significantly by the addition of the P-gp inhibitors vinblastine, quinidine, or verapamil. Tanigawara’s group further demonstrated that while digoxin transport directionality is reduced by cyclosporin inhibition of P-gp, digoxin did not reduce cyclosporin transport.
In other words, digoxin is a substrate of P-gp, but not a modulator (218). Similar studies conducted in different P-gp-expressing cells, including Caco-2 cells, and MDCK-MDR1 cells also identified digoxin as a P-gp substrate (219; 220; 98).

Additional *in vivo* work was done in knockout animal models. For example, Schinkel *et al.* assessed digoxin disposition in *mdr1a* (-/-) mice (131). Following intravenous injection they saw 35-fold greater digoxin accumulation in the brain of knockout mice compared to wild type, demonstrating the efflux activity of blood-brain-barrier P-gp in wild type mice. They also found that *mdr1a* (-/-) mice had 2-fold greater digoxin exposure in the plasma and tissues overall, reflecting slower digoxin elimination in the absence of active excretion by renal P-gp. *In vitro* work by Tsuruoka *et al.* further supported the activity of mouse renal P-gp on digoxin (221). Finally, a study in IV-dosed *mdr1a* (-/-) mice by Kawahara *et al.* also reported significant increase in digoxin AUC and mean residence time, as well as reduced renal and biliary clearance in P-gp-knockout mice (222).

At the turn of the century, human studies were underway to establish digoxin as a clinical P-gp substrate. In 8 healthy volunteers, co-administration of rifampin significantly reduced the AUC of orally dosed digoxin and, to a lesser extent, IV dosed digoxin (55). This was attributed to rifampin induction of P-gp, which was directly measured from duodenal biopsies. Decisive, in depth mechanistic clinical studies performed using segmental intestinal perfusions demonstrated definitively that digoxin is indeed secreted by the P-gp transporter (223; 224). A variety of similar studies with P-gp induction and inhibition all confirmed convincingly that digoxin is a substrate of the human P-gp transporter and that P-gp has a significant impact on digoxin disposition (225-229).

1.4.5 **Digoxin pharmacokinetics**

Digoxin is commonly administered as a commercially available tablet (Lanoxin), which is taken orally. Peak serum concentrations (C<sub>max</sub>) are rapidly achieved 1 to 3 hours following oral administration (230). The C<sub>max</sub> is somewhat delayed when taken with food, but the total amount absorbed is generally unchanged, except in the case of a high fiber meal. By the Biopharmaceutics Classification System (BCS), digoxin is a class II
compound, with high permeability and low aqueous solubility (231). The bioavailability of the oral dose is between 60 percent and 80 percent (232). However, patients with malabsorption syndromes or with certain populations of colonic bacteria may see a reduced digoxin oral bioavailability. Importantly, digoxin is also a substrate of the P-gp efflux transporter, which can limit oral absorption at the apical membrane of enterocytes (233).

The distribution phase of digoxin is between 6 and 8 hours, with a distribution half-life of 0.35 hours (234). The steady-state serum concentrations achieved after distribution are in equilibrium with the digoxin concentrations in the tissues and thus these are the most relevant serum concentrations for evaluating therapeutic and toxic effects. Digoxin has a large $V_d$, showing substantial distribution into tissues (233). Very little digoxin moves into adipose tissue however, and thus dosing should be based on lean body mass rather than total body mass. Not surprisingly then, loss of muscle mass in elderly patients results in a diminished $V_d$. Renal disease and hypothyroidism can also contribute to $V_d$ reduction. Digoxin has been shown to cross both the blood-brain-barrier and the blood-placenta-barrier and is 25% serum protein bound (233).

Digoxin shows very little metabolism, only 13 percent. The primary metabolites are dihydroredigoxin, digoxigenin and bisdigitoxoside and they are produced by non-CYP enzymes. Renal excretion is the major route of digoxin elimination and between 50 and 70 percent of the parent compound is excreted unchanged in the urine (235). Given the importance of the kidney in the elimination of digoxin, its half-life is prolonged in patients suffering from renal failure. The typical half-life in patients with healthy renal function though, is between 1.5 and 2 days (233).

1.4.6 **Digoxin as a model P-gp substrate**

Digoxin’s pharmacokinetics makes it an ideal *in vitro* probe substrate for the P-gp drug transporter. According to the FDA 2006 draft guidance for drug interaction studies, an *in vitro* P-gp probe substrate should be: selective to the P-gp transporter, have low passive membrane permeability, show minimal metabolism, be commercially available, and be safe for *in vivo* studies (17). Additional requirements applicable to human studies
should include a drug that is: safe and well tolerated by healthy subjects, approved for human administration, rapidly absorbed with a short half-life to avoid long clinical studies, minimally plasma protein bound, and quantifiable from plasma and/or urine and/or fecal samples using validated analytical methods (236). Digoxin is a P-gp substrate drug that is commercially available, both as cold- and radiolabelled- drug and it adequately fulfills the aforementioned probe substrate criteria. It remains the recommended probe drug for P-gp interaction studies according to the FDA and is viewed as the gold standard for industry testing (17; 181; 183; 237; 238).

Though used less frequently than digoxin, fexofenadine – a histamine H1-receptor antagonist used for the treatment of seasonal allergic rhinitis – is also an effective P-gp probe drug. It is a demonstrated P-gp substrate: showing directional transport in Caco-2 cells that is suppressed by P-gp inhibitors, as well as significantly increased plasma and tissue levels in MDR1 knockout mice (239-241). It shows minimal metabolism, with 95% of a dose excreted unchanged in the urine and feces (242). Moreover, the 60 mg single oral dose that is commonly used for in vivo studies is safe and tolerable and results in accurate and detectable plasma concentrations (243; 244). Notably though, while fexofenadine is commercially available, it is not available as an intravenous formulation. As a result, fexofenadine has limited in vivo usefulness in distinguishing the activity of intestinal versus renal P-gp. As well, commercially available fexofenadine is a racemic mixture, which may introduce chiral-associated differences in the drug’s pharmacokinetics that are independent of P-gp (245). Moreover, fexofenadine is reported to be a substrate for several other transporters, many of which are expressed in cells commonly used for permeability assay, including organic anion-transporting polypeptide 2B1 (OATP2B1) and multidrug resistance-associated protein 2 and 3 (MRP2 and MRP3). These competing transporters can complicate interpretation of P-gp transport kinetics (246).

1.5 Rationale

It is well appreciated that the activity of membrane transporter proteins plays an important role in drug disposition, a critical determinant of the pharmacological and toxicological profile of all drugs (247; 12). Like drug metabolizing enzymes, drug
transporters are known to mediate significant drug-drug interactions as well as contribute to population variation in pharmacokinetics. P-glycoprotein (P-gp) is a key clinically important and well-characterized efflux transporter, which affects drug absorption, distribution and elimination (112; 12; 114; 115). A great number of clinically relevant, pharmacologically and structurally unrelated drugs are substrates for P-gp. Consequently, the efflux transport activity of P-gp on various drugs and drug candidates is routinely tested using the gold standard in vitro permeability assay across a monolayer of polarized, P-gp expressing Caco-2, LMDR1, or MDCK-MDR1 cells. Different metrics – namely apparent permeability $P_{app}$ and efflux ratio $E_fR$ – are employed to evaluate P-gp transporter activity in this assay, in order to identify P-gp substrates or modulators and to extrapolate to in vivo and clinical pharmacokinetics. However, comparative assessment of how well these metrics can specifically characterize the efflux transport activity of P-gp is limited in the literature. In one study investigating the sources of inter-lab variability in Caco-2 cell intestinal model predictions, Hayeshi et al. reported on the correlation between varied P-gp mRNA expression levels in Caco-2 monolayers and the corresponding P-gp activity estimates calculated by $P_{app}$ and by $E_fR$ (248). Taipalensuu et al. also reported on the correlation between efflux ratio and P-gp protein expression in Caco-2 monolayers (249). But, there are no studies that evaluate the efficacy of $P_{app}$ or $E_fR$ to estimate P-gp activity across the various commonly used monolayer cell types. Our study compares traditional metrics of P-gp activity in Caco-2, LLCPK and LMDR1 monolayer permeability assays, against a mechanistically-based compartmental modeling approach, which generates a clearance $CL_{P-gp}$ to quantitatively describe the intrinsic efflux activity of the P-gp transporter. We believe that a modeled clearance approach is a superior metric for the permeability assay because it does not rely on the potentially erroneous assumption that intracellular concentration is equal to basolateral concentration. Rather, the modeled approach specifically and quantitatively estimates P-gp activity from a fitted intracellular concentration. At the same time, it accounts for uptake transport parameters as well as other passive and active transport processes that may be specific to the different cell lines that are used for monolayer permeability assays. In this way, modeled $CL_{P-gp}$ should be transferable between different monolayer cell types (e.g. Caco-2, LLCPK, and LMDR1) and in vivo, whereas $P_{app}$ and $E_fR$ values
derived from different systems may not interrelate well. Compared to the qualitative P-gp transporter activity assessments offered by $P_{app}$ and EfR, modeled $CL_{P-gp}$ is likely more useful for the precise quantitative evaluation of the activity of the P-gp transporter in cell monolayer permeability assays and ultimately more useful for quantitative *in vitro* to *in vivo* extrapolation. To compare the merit of our model against the standard metrics, we conducted monolayer permeability assays across Caco-2, LLCPK, and LMDR1 cell monolayers that had a range of P-gp expression level and we employed unidirectional permeability, efflux ratio, and modeled clearance metrics to estimate P-gp activity in each assay. We then performed a statistical analysis to compare all metrics for overall validity and sensitivity across cell systems.

1.6 **Objectives**

1. To establish multiple cell monolayer permeability *in vitro* systems with different levels of P-gp expression/activity.

2. To evaluate P-gp efflux activity in the different cell systems using the traditional metrics and a modeled intrinsic P-gp clearance.

3. To compare the validity and sensitivity of the different metrics of efflux transporter activity across cell systems.

1.7 **Hypothesis**

We hypothesize that modeled clearance ($CL_{int(Transport)}$) is a more valid and sensitive measure of P-gp activity in the *in vitro* cell monolayer permeability assay than $P_{app}$ and EfR.
1.8 References


47. Rosenberg MF, Callaghan R, Ford RC, Higgins CF (1997) Structure of the multidrug resistance P- glycoprotein to 2.5 nm resolution determined by electron
microscopy and image analysis. Journal of Biological Chemistry 272: 10685-94


57. Schinkel AH, Smit JJ, van Tellingen O (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77: 491–502


109. Hsiao P, Bui T, Ho RJ, Unadkat JD (2007) In vitro to in vivo prediction of p-glycoprotein based drug interactions at the human and rodent blood-brain barrier. Drug Metabolism and Disposition 34: 786–792


143. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition 27(12): 1381-91


206. Su SF, Huang JD (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metabolism and Disposition 24: 142–147


241. Tahara H, Kusuhara H, Fuse E, Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier,
but only a limited role in its biliary excretion. Drug Metabolism and Disposition 33(7): 963-8


Chapter 2

QUANTITATIVE ESTIMATION OF P-GLYCOPEPTIDE-MEDIATED DRUG TRANSPORT IN THE MONOLAYER PERMEABILITY ASSAY BY MECHANISTICALLY MODELED INTRINSIC CLEARANCE

2.1 Introduction

Interindividual differences in drug response and toxicity continue to be a challenge to optimal drug therapy (1). It is well appreciated that differences in drug action among patients relate to variability in the levels of drug in the blood. Cell membrane-bound transporter proteins play an important role in drug absorption, distribution, and excretion pharmacokinetic processes, which are critical determinants of drug levels and hence the pharmacological and/or toxicological profile of all drugs and xenobiotics (2; 3). Many common polymorphisms in drug transporters have been linked to altered drug pharmacokinetics and transporters are also the basis of many clinically relevant drug-drug interactions (DDIs) (3). Whole cell and expression system in vitro assays of drug metabolizing enzyme activities yield kinetic information that is essential for in vitro to in vivo extrapolation (IVIVE) of drug levels and for mechanistic understanding and prediction of DDIs and pharmacokinetics in the clinical setting (4; 5). Interestingly though, such biochemical characterization of drug transporter activity today remains inadequate, despite the important role of transporters in drug pharmacokinetics (5).

P-glycoprotein (P-gp), encoded by the Multidrug Resistance 1 (MDR1, ABCB1) gene, is the most clinically important and well-characterized efflux transporter, responsible for pumping drugs from inside cells to the outside milieu. P-gp is widely expressed on the apical membrane in tissues such as liver, kidney, intestines, and at the blood-brain-barrier, indicating its important role in drug disposition. A large number of pharmacologically and structurally unrelated drugs are substrates for P-gp, including: anti-cancer agents, steroid hormones, antimicrobial agents, opioids, immunosuppressants, antiarrhythmics, antihistamines, cholesterol-lowering statins, and HIV protease inhibitors, to name a few (6).
Given the clinical relevance of P-gp, an initial \textit{in vitro} assay of P-gp transporter activity is typically performed for a drug in order to predict P-gp-drug interaction and guide further \textit{in vivo} studies. Convention has been to measure drug flux across a tight monolayer of apical-basolateral polarized cells that have apical P-gp expression (7; 8). The apparent permeability (P\textsubscript{app}) of a drug across the monolayer is estimated from the appearance of drug in the receiver compartment over time [Equation 1.12]. Due to polarized expression of P-gp efflux transporter on the apical membrane, a P-gp substrate drug would be expected to show increased P\textsubscript{app} in the basolateral-apical direction (P\textsubscript{app(B-A)}) and decreased P\textsubscript{app} in the apical-basolateral direction (P\textsubscript{app(A-B)}). The ratio of P\textsubscript{app(B-A)}/P\textsubscript{app(A-B)}, known as the efflux ratio (EfR) [Equation 1.13], is then said to estimate P-gp transport activity on a substrate drug; the assumption being that EfR and P\textsubscript{app(B-A)} are proportional to P-gp activity and P\textsubscript{app(A-B)} is inversely proportional to P-gp activity (8).

\begin{equation}
\text{P}_{\text{app}} = \frac{(\Delta C_{D,0})}{(S \times C_{D,0})}
\end{equation}

\begin{equation}
\text{EfR} = \frac{P_{\text{app(B-A)}}}{P_{\text{app(A-B)}}}
\end{equation}

While EfR, P\textsubscript{app(B-A)}, and P\textsubscript{app(A-B)} can effectively identify most P-gp substrates, specific estimation of P-gp activity may be limited. Apparent permeabilities and efflux ratios, which are measured directly from flux across the monolayer, view the system as a single barrier with drug actively transported directly from the donor compartment to the receiver compartment. In reality it is the intracellular drug concentration, not the donor compartment concentration that interacts with P-gp on the apical membrane. Therefore, EfR, P\textsubscript{app(B-A)}, and P\textsubscript{app(A-B)} do not account for the potentially rate limiting active uptake processes on the basolateral or apical membranes that move drug from the donor compartment into the intracellular compartment, where drug-P-gp interaction occurs. Consequently, EfR, P\textsubscript{app(B-A)}, and P\textsubscript{app(A-B)} metrics fail to specifically characterize P-gp transport and thus may not show direct proportionality with P-gp transporter activity and expression (9; 10).

We propose utilizing a mathematical model that incorporates all potentially rate limiting active and passive transport processes occurring at both the apical and basolateral membranes (Figure 2.1). By fitting flux data to this model, we can estimate the kinetics
of P-gp transport from the intracellular space. The output parameter from this exercise $$$CL_{P-gp}$$$, P-gp intrinsic clearance, is then a mechanistically-based quantitative estimate of P-gp transporter activity. In order to compare this modeled approach for P-gp activity estimation with the typical metrics, we conducted several monolayer permeability assays with a range of P-gp expression and appraised the correlation of $$P_{app}$$, EfR, and $$CL_{P-gp}$$ with P-gp expression in each assay. In theory, the level of P-gp expression on the apical membrane of polarized cells should be directly proportional to measured P-gp transport activity when the transporter is not saturated. We hypothesize that the modeled clearance ($$CL_{P-gp}$$) is a superior metric of P-gp activity compared to $$P_{app}$$ or EfR.
Figure 2.1. Schematic presentation of the compartmental model, with apical (A), basolateral (B), and cell (C) compartments represented. CL parameters define the transit efficiencies between compartments of volume V and drug concentration C.
2.2 Materials and Methods

2.2.1 Materials

Human colorectal adenocarcinoma [Caco-2] and porcine kidney epithelial [LLCPK] cells were obtained from American Type Culture Collection ATCC (Manassas, VA). LLCPK cells overexpressing MDR1 [LMDR1] were a generous gift from Dr. A.H. Schinkel (The Netherlands Cancer Institute, Amsterdam, Holland) and Dr. E. Schuetz (St. Jude Children’s Research Hospital, Memphis, TN). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, nonessential amino acids (NEAA) and 0.05% trypsin-EDTA were all purchased from Life Technologies (Grand Island, NY). Vincristine sulfate with a purity exceeding 97.5 [HPLC], 1α,25-dihydroxyvitamin D3 with purity exceeding 99% [HPLC], thiazolyl blue tetrazolium bromide (MTT) with purity exceeding 98% [HPLC], digoxin with purity exceeding 96.4% [HPLC], and protease inhibitor were all sourced from Sigma-Aldrich (St. Louis, MO). Transwell cell culture inserts (12-well, 0.4 um) were purchased from VWR-International (Mississauga, ON). [3H]-Digoxin (specific activity, 21.8 Ci/mmol), was obtained from PerkinElmer Life & Analytical Sciences (Boston, MA). [14C]-Inulin (specific activity, 8.5mCi/mmol), with purity exceeding 95% [HPLC] was from Moravek Biochemicals (Brea, CA). Ultima Gold scintillation cocktail was purchased from PerkinElmer (Waltham, MA). Thermo Scientific Pierce IP lysis buffer and Thermo Scientific Restore Western Blot Stripping Buffer were obtained from Fischer Scientific (Ottawa, ON). Western Blocking Reagent was purchased from Roche (Indianapolis, IN). C219 monoclonal p-glycoprotein antibody was purchased from Covance (Dedham, MA). Polyclonal goat anti-actin antibody (C-11) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Goat anti-mouse IgG (H + L)-HRP conjugate was purchased from BioRad Canada (Mississauga, ON). Amersham ECL select western blotting detection reagent was purchased from GE Healthcare UK (Little Chalfont, Buckinghamshire).

2.2.2 Cell Culture

Caco-2 (passage no. 20-35), LLCPK (passage no. 5-15), and LMDR1 (passage no. 5-15) cells were cultured in DMEM supplemented with 50 ug/ml streptomycin, 50 U/mL penicillin and 10% fetal bovine serum. LMDR1 culture media was also supplemented
with 10% NEAA and 640 nM vincristine to maintain P-glycoprotein expression. Cells were incubated at 37°C in 5% CO₂ in a humidified environment.

2.2.3 MTT Assay

MTT assay was performed on Caco-2 cells in 96-well plates with approximately 1.2×10⁴ cells per well. Cells were treated in triplicate with 0 nM to 1500 nM 1α,25(OH)₂D₃ every other day for 14 days. On day 15 cells were washed with phosphate-buffered saline (PBS) and 25 µL of 5 mg/mL MTT in PBS was added to each well. The plates were incubated for 4 h at 37 °C and the formazan formed was dissolved in 50 µL of dimethyl sulfoxide (DMSO). The background absorbance at 670 nm was subtracted from the absorbance at 569 nm to obtain the raw absorbance data (Thermo Multiskan spectrophotometer).

2.2.4 Digoxin Flux Studies

Cells were seeded in 12-well plates at a density of 90,000 cells per 0.4-µm cell culture insert and grown for 14 days with media changes every 2 days. Each time the media was changed, Caco-2 cells were treated with 0 nM (Caco-2 (0nM)), 10 nM (Caco-2 (10 nM)), or 100 nM (Caco-2 (100 nM)) of the P-gp inducer 1α,25(OH)₂D₃ dissolved in DMSO. Approximately 1 h before the start of a transport experiment, the media was removed from each compartment (apical and basal) and washed and replaced with pH 7.4 Krebs-Henseleit Bicarbonate Buffer (KHB). Transport was initiated by removing the KHB and replacing it with 700 µl of KHB with or without 5 uM digoxin (3.5 µmol of digoxin) + 5.7 nM [³H]-digoxin to the appropriate compartment in triplicate. [¹⁴C]-Inulin was included in each plate in triplicate as a marker of paracellular flux. The cells were incubated at 37°C with 5% CO₂ in a humidified environment, and 25-µl aliquots were removed hourly from each compartment over 4 h. Each aliquot was mixed with 5 mL of Ultima Gold scintillation cocktail and counted using a PerkinElmer TriCarb2900 TR liquid scintillation counter.
2.2.5 Estimation of P-gp Activity

2.2.5.1 Conventional Estimates: $P_{app(A-B)}$, $P_{app(B-A)}$, and EfR

Apparent permeability ($P_{app}$) in both directions was determined as follows:

$$P_{app} = \frac{dA_R}{dt}/(S \times C_{D,0}) \ [\text{cm/s}] \ [1.12]$$

where $dA_R/dt$ is the rate of drug ($[^3H]$-digoxin or $[^14C]$-inulin) appearance in the receiver compartment, $S$ is the surface area of the cell culture insert, and $C_{D,0}$ is the initial concentration added to the donor compartment. This model is derived from Fick’s first law of diffusion, assuming a constant linear concentration gradient across a single barrier and a sink condition. Efflux ratio (EfR) was determined as follows:

$$\text{EfR} = \frac{P_{app(B-A)}}{P_{app(A-B)}} \ [1.13]$$

where $P_{app(B-A)}$ is the apparent permeability in the basolateral to apical direction and $P_{app(A-B)}$ is the apparent permeability in the apical to basolateral direction.

2.2.5.2 Mathematical Modeling of Transport Intrinsic clearance: $CL_{P-gp}$

The three-compartment kinetic model (Figure 2.1) uses a set of mass balance differential equations [Equations 2.1-2.3] to describe digoxin flux in a transwell as a one-dimensional process between an apical, a cellular, and a basolateral kinetic compartment. The volumes used for the apical, cell, and basolateral compartments were fixed at 700 µL, 2.76 µL and 700 µL respectively, and drug dispersion within the compartments was viewed as rapid and even. The cell volume was estimated using a previously reported geometric approach of multiplying cell heights by the surface area of cell culture inserts (9). $CL_{P-gp}$ describes the efflux clearance at the apical membrane that is mediated by P-gp. $CL_{A-C}$ and $CL_{C-B}$ describe the net clearance due to all other transcellular transport processes (excluding P-glycoprotein-mediated clearance) across the apical membrane and the basolateral membrane respectively; we assumed symmetrical transcellular clearance at both membranes. Rate equations describing the model (Figure 2.1) were solved numerically using the Episode (Adams) integrator (Scientist, Micromath, Salt Lake City, Utah). The P-gp clearance parameter ($CL_{P-gp}$) and both net basolateral and apical clearance parameters ($CL_{A-C}$ and $CL_{C-B}$) were estimated by simultaneous least
squares fitting of [3H]-digoxin flux data for drug administration in both directions to the model. Fitting of the paracellular clearance parameter (CL\textsubscript{A-B}) was done separately using simultaneous fitting of bidirectional [14C]-inulin flux data, with all other clearance parameters set to zero. All fitted parameters were constrained to be positive numbers. The differential equations that describe the model are as follows:

In the apical compartment

\[ V_A \frac{dC_A}{dt} = -C_A CL\textsubscript{A-C} + C_C CL\textsubscript{A-C} - C_A CL\textsubscript{A-B} + C_B CL\textsubscript{A-B} + C_C CL\textsubscript{P-gp} \quad [2.1] \]

In the cellular compartment

\[ V_C \frac{dC_C}{dt} = -C_C CL\textsubscript{A-C} + C_A CL\textsubscript{A-C} - C_C CL\textsubscript{C-B} + C_B CL\textsubscript{C-B} - C_C CL\textsubscript{P-gp} \quad [2.2] \]

In the basolateral compartment

\[ V_B \frac{dC_B}{dt} = -C_B CL\textsubscript{C-B} + C_C CL\textsubscript{C-B} - C_B CL\textsubscript{A-B} + C_A CL\textsubscript{A-B} \quad [2.3] \]

Where \( \frac{dC_A}{dt}, \frac{dC_C}{dt} \) and \( \frac{dC_B}{dt} \) is the rate of change of drug concentration in the apical, cell and basolateral compartments respectively; \( V_A, V_C \) and \( V_B \) are the volumes in each compartment; and \( C_A, C_C \) and \( C_B \) are the drug concentrations. Where CL\textsubscript{A-B} represents the paracellular clearance; CL\textsubscript{A-C} and CL\textsubscript{C-B} represent the non-P-gp transcellular clearance across the apical and basolateral membranes respectively; and CL\textsubscript{P-gp} represents the P-glycoprotein-mediated apical efflux clearance.

2.2.6 Immunoblotting and P-gp Quantitation

At the end of each transport experiment, the cells were collected from cell culture insert membranes, washed with ice cold PBS and then lysed in lysis buffer containing protease inhibitor by the Thermo Scientific IP lysis buffer protocol. The whole-cell lysates were then stored at -80 °C for future analysis by western blot. Control Caco-2 cells were grown in a 10 cm plate, lysed with the Thermo Scientific IP lysis buffer protocol and the whole cell lysate was loaded on every western blot. Protein concentrations of all lysates were determined by Pierce BCA protein assay (Fisher Scientific, Whitby, ON). Forty µg of control Caco-2, 20 µg of LLCPK, Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100
nM) and 5 µg of LMDR1 whole cell lysate protein was separated on a NuPAGE 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA). Detection of P-glycoprotein expression was performed by overnight incubation with anti-P-glycoprotein antibody (C219), diluted 1:500 in PBS with 0.1% Tween 20 and 10% western blocking reagent. To confirm equal loading of lysates, the blot was stripped and incubated with a polyclonal goat anti-actin antibody, at a dilution of 1:20,000 (C-11; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Actin expression could not be assumed to be constant between LLCPK and Caco-2 cell types, thus normalizing to actin was not performed. Horseradish peroxidase-linked anti-mouse or anti-goat antibodies (Biorad) were used as the secondary antibodies. Blots were visualized using Amersham ECL Western blotting system (GE) and a Kodak ImageStation 4000 MM (Eastman Kodak Company, Rochester, New York). Protein expression was quantified by densitometry with ImageJ. All samples were quantified relative to the control Caco-2 whole cell lysate loaded on each blot. All quantified densitometry values were multiplied by a loading correction factor, to account for the different amounts of protein loaded between cell types.

2.2.7 Comparison of P-gp Transport Activity Metrics

For each transwell experiment, the derived CL\textsubscript{P-gp} value was plot against the measured P-gp expression. CL\textsubscript{P-gp} values vs. protein expression data set generated from the 5 different transwell experiment types (Caco-2 (0 nM), Caco-2 (10 nM), Caco-2 (100 nM), LLCPK, and LMDR1) was then fit by linear regression using Prism 5.0 (GraphPad Software Inc, San Diego, CA). The same process was repeated for P\textsubscript{app(A-B)}, P\textsubscript{app(B-A)} and EfR estimates of P-gp activity respectively. The lines of best fit were then compared for goodness of fit ($r^2$) and slope.

2.2.8 Statistical Analysis

Statistical differences between group parameters were determined by 1-way ANOVA or 2-way ANOVA, using Boneferroni’s multiple comparison test as appropriate (GraphPad Software Inc, San Diego, CA). A $P$ value of <0.05 was considered statistically significant.
2.3 Results

2.3.1 Cell Monolayer Viability

The $^{14}$C-inulin permeability values for the cell monolayers used in the transport experiments are displayed in Table 2.1. Evidently, Vitamin D treatment (10 nM or 100 nM) did not significantly alter $^{14}$C-inulin permeability across Caco-2 cell monolayers. All Caco-2 cell conditions showed significantly higher $^{14}$C-inulin permeability than LLCPK and LMDR1 monolayers. But, all five monolayer conditions demonstrated acceptable membrane integrity, with inulin permeabilities $\leq 5\times10^{-6}$ cm/s.

Viability of Caco-2 cells treated with various concentrations of 1,25(OH)$_2$D$_3$ for 14 days was assessed by MTT assay (Figure 2.2). Concentrations as high as 500 nM 1,25(OH)$_2$D$_3$ were tolerable by Caco-2 cells, with only a 15% rate of cytotoxicity. This concentration was fivefold higher than the concentration used in our high vitamin D treatment condition.

2.3.2 Transport Experiments

$^3$H-Digoxin transport across the LLCPK and LMDR1 cell monolayers is shown in Figure 2.3. For $^3$H-digoxin movement out of the donor compartment (Figure 2.3A) there was a trend towards greater flux in the basolateral to apical (B-A) direction in the LMDR1 cells as compared to LLCPK. As well, flux in the apical to basolateral (A-B) direction was significantly smaller in the LMDR1 cells. In the receiver compartment (Figure 2.3B) flux in both directions was significantly different between the two cell types. The LMDR1 cells had comparatively greater B-A flux and less A-B flux than the LLCPK cells. Overall, the disparity in B-A versus A-B flux was significantly greater in the LMDR1 cells.

$^3$H-Digoxin transport across Caco-2 cells treated with 0 nM, 10 nM and 100 nM 1,25(OH)$_2$D$_3$ is shown in Figure 2.4. From the donor compartment (Figure 2.4A) A-B flux in the Caco-2 cells treated with 100 nM 1,25(OH)$_2$D$_3$ was significantly decreased compared to the Caco-2 cells not treated with 1,25(OH)$_2$D$_3$. Basolateral to apical flux however, did not significantly differ between the treatment groups. In the receiver
Table 0.1. Apparent permeability coefficients and net efflux ratio of bidirectional [\(^{14}\)C]-inulin transport over a 4 hour time course, across the various cell monolayers.

<table>
<thead>
<tr>
<th>Monolayer Cell Type</th>
<th>(P_{\text{app}(A-B)} \times 10^{-6} \text{ cm/s} )</th>
<th>(P_{\text{app}(B-A)} \times 10^{-6} \text{ cm/s} )</th>
<th>EfR</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLCPK</td>
<td>3.122 ± 0.134</td>
<td>2.989 ± 0.153(^a)</td>
<td>0.948 ± 0.014</td>
</tr>
<tr>
<td>LMDR1</td>
<td>3.886 ± 0.585</td>
<td>2.481 ± 0.175(^a)</td>
<td>0.867 ± 0.079</td>
</tr>
<tr>
<td>Caco-2 (0 nM)</td>
<td>4.557 ± 0.277</td>
<td>4.430 ± 0.359(^b)</td>
<td>0.953 ± 0.034</td>
</tr>
<tr>
<td>Caco-2 (10 nM)</td>
<td>4.142 ± 0.291</td>
<td>4.067 ± 0.285(^b)</td>
<td>0.982 ± 0.002</td>
</tr>
<tr>
<td>Caco-2 (100 nM)</td>
<td>4.056 ± 0.299</td>
<td>4.121 ± 0.275(^b)</td>
<td>1.026 ± 0.024</td>
</tr>
</tbody>
</table>

\(^{a,b}\) \(p < 0.05\) compared between monolayer cell types

Caco-2 cells were treated every other day with culture media only (Caco-2 (0 nM)), or with culture media + 10 nM (Caco-2 (10 nM)) or + 100 nM (Caco-2 (100 nM)) \(1,23(\text{OH})_2\text{D}_3\) for 2 weeks. Data are presented as mean ± S.E. (n=6).
Figure 2.2. The cytotoxic effect of vitamin D (1,25(OH)\(_2\)D\(_3\)) on cultured Caco-2 cells. Caco-2 cells (passage 15-35) were treated with various concentrations of vitamin D every other day for 14 days and cell survival was assessed by MTT assay. Data are expressed as the percentage of viability compared to control non-treated cells performed in the same experiment. Data are presented as mean ± S.D. (n = 1 experiment, 3 technical replicates).
Figure 2.3. Cumulative amounts of $[^3]$H-digoxin transported from the donor compartment (A) and into the receiver compartment (B) of the LLCPK and LMDR1 cell monolayer, for the A-B and B-A direction, over a 4 hour time course. The transport study was performed on day 15. Data are presented as mean ± S.E. (n=4-6).

*, p < 0.05 between A-B - LLCPK and A-B - LMDR1; †, p < 0.001 between B-A - LLCPK and B-A - LMDR1.
Figure 2.4. Cumulative amounts of [³H]-digoxin transported from the donor compartment (A) and into the receiver compartment (B) of the Caco-2 cell monolayer, for the A-B and B-A direction, over a 4 hour time course. Prior to transport, Caco-2 cells were treated every other day with culture media only (●/▼), or with culture media + 10 nM (■/♦) or + 100 nM (▲/○) 1,25(OH)₂D₃ for 2 weeks. The transport study was performed on day 15. Data are presented as mean ± S.E. (n≥4).

*, p <0.05 between A-B - Caco-2 (0 nM) and A-B - Caco-2 (100 nM); †, p < 0.05 B-A - Caco-2 (10 nM) and B-A - Caco-2 (100 nM).
compartment (Figure 2.4B) A-B flux was significantly lower and B-A flux was significantly higher in the Caco-2 (100 nM) cells as compared to the Caco-2 (0 nM) cells. B-A flux was also significantly smaller in the Caco-2 (10 nM) cells as compared to the Caco-2 (100 nM) cells. Evidently, the disparity in B-A versus A-B flux was significantly larger in Caco-2 cells treated with 100 nM $1,25(OH)_2D_3$ versus Caco-2 cells treated 0 nM or 10 nM $1,25(OH)_2D_3$.

2.3.3 P-gp Protein Expression

Figure 2.5 shows C219 antibody western blots of the whole cell lysates collected from the various transwell cell monolayers after each transport experiment; the 170 kDa P-gp protein was expressed in all cell types in a range increasing from LLCPK < Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100 nM) < LMDR1. Table 2.2 shows the densitometry quantification of the P-gp western blots, corrected for the different sample amounts loaded. P-gp expression was generally consistent across experiment days; the standard deviation for P-gp expression within a cell type was between 5 and 10 percent. On average LLCPK cells showed 25 fold less P-gp expression than the LMDR1 cells stably transfected with the $MDR1$ gene. Caco-2 cells showed about two fold more expression than LLCPK cells, but treatment with 10 nM and 100 nM $1,25(OH)_2D_3$ induced approximately a 2-fold and 3-fold increase in Caco-2 cell P-gp expression, respectively.

2.3.4 Permeability and Efflux Ratios

We generated the apparent permeability values of digoxin across the different monolayers from flux data (Figure 2.6). Comparing bidirectional permeability between the LLCPK and the LMDR1 cell monolayers (Figure 2.6A), B-A permeability was significantly higher than A-B permeability in both cell types, but A-B permeability was significantly depressed, by 12 fold, in the LMDR1 cells versus the LLCPK cells. P-gp expression in the LMDR1 cells did not produce a significant increase in the B-A permeability of digoxin above that seen in the LLCPK cells. In examination of bidirectional permeability in the Caco-2 cells that were treated with various concentrations of $1,25(OH)_2D_3$ (Figure 2.6B), B-A permeability was again significantly higher than A-B permeability in all cell monolayers. Caco-2 cells treated with 10 nM and
Figure 2.5. Western blots, using a mouse monoclonal anti-P-gp antibody (C219) (I) and a polyclonal goat anti-actin antibody (C-11) (II), of transwell monolayer cell lysates from experiment Day 1 (A), Day 2 and 3 (B), Day 4 (C), Day 5 (D), and Day 6 (E).
monolayer lysates in (A), (C), (D), and (E) were loaded as LLCPK [Lane 1], LMDR1 [Lane 2], Caco-2 (0 nM) [Lane 3], Caco-2 (10 nM) [Lane 4] and Caco-2 (100 nM) [Lane 5]; in (B) they were loaded as LLCPK (Day 2) [Lane 1], LMDR1 (Day 2) [Lane 2], Caco-2 (0 nM) (Day 2) [Lane 3], and LLCPK (Day 3) [Lane 4]. The same control Caco-2 cell lysate was loaded for densitometry comparison on every blot [Lane 0]. 40 µg of protein was loaded for all Caco-2 control lysates; 5 µg of protein was loaded for all LMDR1 monolayer lysates; 20 µg was loaded for all other monolayer lysates.
**Table 0.2.** Relative P-gp and Actin protein expression in transwell monolayer cells collected from each experiment day, as compared to the control Caco-2 cell lysate.

<table>
<thead>
<tr>
<th>Day</th>
<th><strong>P-gp</strong></th>
<th><strong>LDMR1</strong></th>
<th><strong>Caco-2 (0nM)</strong></th>
<th><strong>Caco-2 (10nM)</strong></th>
<th><strong>Caco-2 (100nM)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.553</td>
<td>13.174</td>
<td>1.182</td>
<td>2.139</td>
<td>3.431</td>
</tr>
<tr>
<td>Actin</td>
<td>1.028</td>
<td>1.032</td>
<td>1.024</td>
<td>1.040</td>
<td>1.014</td>
</tr>
<tr>
<td>2</td>
<td>0.545</td>
<td>11.610</td>
<td>1.057</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Actin</td>
<td>0.997</td>
<td>0.999</td>
<td>0.573</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>0.535</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Actin</td>
<td>1.038</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>0.585</td>
<td>12.601</td>
<td>1.159</td>
<td>2.308</td>
<td>3.301</td>
</tr>
<tr>
<td>Actin</td>
<td>1.053</td>
<td>1.050</td>
<td>0.979</td>
<td>1.048</td>
<td>0.958</td>
</tr>
<tr>
<td>5</td>
<td>0.446</td>
<td>13.928</td>
<td>0.585</td>
<td>2.144</td>
<td>3.041</td>
</tr>
<tr>
<td>Actin</td>
<td>1.094</td>
<td>1.014</td>
<td>0.998</td>
<td>1.019</td>
<td>0.972</td>
</tr>
<tr>
<td>6</td>
<td>0.621</td>
<td>15.563</td>
<td>0.975</td>
<td>2.090</td>
<td>3.471</td>
</tr>
<tr>
<td>Actin</td>
<td>1.054</td>
<td>1.088</td>
<td>0.991</td>
<td>0.975</td>
<td>1.008</td>
</tr>
<tr>
<td>Avg</td>
<td><strong>P-gp</strong></td>
<td>0.543</td>
<td>13.575</td>
<td>1.072</td>
<td>2.195</td>
</tr>
<tr>
<td>SD</td>
<td>0.059</td>
<td>1.873</td>
<td>0.096</td>
<td>0.097</td>
<td>0.194</td>
</tr>
</tbody>
</table>

*Cells from transwell experiments with leaky monolayers ([14C]-inulin permeability > 5 × 10⁻⁶ cm/s) were excluded from the study.*
100 nM 1,25(OH)\(_2\)D\(_3\) showed respectively 2 fold and 2.7 fold less A-B permeability than untreated Caco-2 cells, but did not show significantly different A-B permeability compared to each other. Conversely, in the B-A direction Caco-2 cells treated with 10 nM 1,25(OH)\(_2\)D\(_3\) did show significantly less permeability than 100 nM treated cells, by 1.3 fold, but 10 nM treated cells did not show significantly different B-A permeability compared to untreated Caco-2 cells. Comparing all cell monolayers in the A-B direction (Figure 2.6C), digoxin permeability was significantly higher in LLCPK cells than all other cell conditions. A-B permeability was significantly diminished by 2.8 fold in LMDR1 cells compared to untreated Caco-2 cells, but not significantly so when compared to Caco-2 cells treated with 1,25(OH)\(_2\)D\(_3\). For all monolayers in the B-A direction (Figure 2.6D), 100 nM 1,25(OH)\(_2\)D\(_3\) treated Caco-2 cells showed significantly higher B-A permeability, but a significant difference was not seen between the B-A permeabilities of any of the other conditions. There was a slight trend though towards decreased B-A permeability in the LLCPK cells.

Efflux ratios generated from the flux data are presented in Figure 2.7. LLCPK monolayer showed an EfR close to 1, which was significantly smaller than the LMDR1 monolayer by 5.4 fold and smaller than the three Caco-2 monolayer conditions by 2 fold, 3.7 fold, and 6.9 fold respectively. There was a significant trend towards increasing EfR values in response to increasing 1,25(OH)\(_2\)D\(_3\) concentration. Untreated Caco-2 cells had the lowest EfR, Caco-2 cells treated with 10 nM 1,25(OH)\(_2\)D\(_3\) were 1.7 fold higher than untreated. The EfR of Caco-2 (100 nM) cells was 2.6 fold higher than untreated Caco-2 cells and was not significantly different from the LMDR1 cell monolayer EfR.

2.3.5 Modeled Clearance

Generation of the CL\(_{\text{P-gp}}\) values required fitting of the transport data to our kinetic compartmental model [Equations 2.1-2.3], which encompasses parameters for paracellular clearance between an apical and basolateral compartment, as well as parameters for clearance at separate apical and basolateral barriers. An average digoxin
Figure 2.6. Apparent permeability coefficients for the transport of [$^3$H]-digoxin, over a 4 hour time course, in the A-B and B-A direction across LLCPK and LMDR1 cell monolayers (A), in the A-B and B-A direction across Caco-2 (0 nM), Caco-2 (10 nM) and Caco-2 (100 nM) cell monolayers (B), in the A-B direction across LLCPK, LMDR1, Caco-2 (0 nM), Caco-2 (10 nM) and Caco-2 (100 nM) cell monolayers (C), and in the B-A direction across LLCPK, LMDR1, Caco-2 (0 nM), Caco-2 (10 nM) and Caco-2 (100 nM) cell monolayers (D). Caco-2 cells were treated every other day with culture media only [Caco-2 (0 nM)], or with culture media + 10 nM [Caco-2 (10 nM)] or + 100 nM [Caco-2 (100 nM)] 1,25(OH)$_2$D$_3$ for 2 weeks. Data are presented as mean ± S.E. (n=4-6). Permeabilities with a different superscript letter (a, b, c, or d) are significantly different; p<0.05.
Figure 2.7. Efflux ratio of bidirectional [³H]-digoxin transport for 4 hours across the different cell monolayers. Data are presented as mean ± S.E. (n ≥ 4). EfRs with a different superscript (a, b, c, or d) are significantly different; p<0.05.
paracellular clearance parameter, CL$_{A-B}$, was estimated for each transwell cell type from fit of average $[^{14}\text{C}]-\text{inulin}$ transwell flux data to the same compartmental model. Using these fitted CL$_{A-B}$ values, the model was able to simulate the average $[^{14}\text{C}]-\text{inulin}$ transport data very well for all cell types (Figure 2.8). Fixing these CL$_{A-B}$ values as the paracellular clearance parameters in our digoxin compartmental model, we then fit the models to the average digoxin transport data for each cell type in order to generate average transcellular clearance parameters CL$_{A-C}$, CL$_{C-B}$, and CL$_{P-gp}$. Model simulation using these fitted CL$_{A-C}$, CL$_{C-B}$, and CL$_{P-gp}$ parameter values also matched the average digoxin transport data quite well for all cell types (Figures 2.9 and 2.10).

As was seen with EfR, modeled P-gp clearance (CL$_{P-gp}$) values increased from LLCPK < Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100 nM) < LMDR1 (Figure 2.11A). CL$_{P-gp}$ in LMDR1 cells was 14.3 fold greater than in LLCPK cells, but we only see a small non-significant 1.5 fold difference between modeled CL$_{P-gp}$ for LLCPK and Caco-2 (0 nM) cells. Similar values of CL$_{P-gp}$ are seen between Caco-2 (0 nM) and Caco-2 (10 nM). Treatment with 100 nM of vitamin D yielded a significantly greater CL$_{P-gp}$, 3.0 fold higher than untreated Caco-2 cells.

In agreement with the $[^{14}\text{C}]-\text{inulin}$ permeability data (Table 2.1), the modeled values for paracellular clearance, CL$_{A-B}$, were fairly consistent across all cell types, but higher in the 3 different Caco-2 cell groups (Figure 2.11D). In contrast, the modeled non-P-gp transcellular clearance was not uniform across cell types; CL$_{A-C}$ and CL$_{C-B}$ parameters were very similar between LLCPK and LMDR1 cells, but in Caco-2 (0 nM) cells CL$_{A-C}$ and CL$_{C-B}$ was around 4 fold and 2 fold greater respectively (Figure 2.11B and C). Evidently, treatment with vitamin D in the Caco-2 (10 nM) and Caco-2 (100 nM) groups reduced the CL$_{A-C}$ and CL$_{C-B}$ down to levels similar to that seen in LLCPK and LMDR1 cells.

Estimates of P-gp activity made by compartmental modelling as well as the estimates made by traditional permeability and efflux ratio methods for all transport experiments are summarized in Tables 2.3 and 2.4.
Figure 2.8. Model fits of inulin transport across LLCPK (A), LMDR1 (B), Caco-2 (0 nM) (C), Caco-2 (10 nM) (D), and Caco-2 (100 nM) (E) monolayers, using Equations 2.1-2.3, with a $CL_{A-B}$ parameter value fit from average $[^{14}C]$-inulin transport data. Solid lines and broken lines represent simulations of the apical dosed and basolateral dosed inulin transport respectively. □ and ▲ represent apical and basolateral dosed inulin data.
points respectively. Data points presented are the average of 6 transport experiments ± SE.
Figure 2.9. Model fits of digoxin transwell transport across LLCPK (A) and LMDR1 (B) cell monolayers out of the donor compartment (I) and into the receiver compartment (II), using Equations 2.1-2.3, with CL_{P-gp}, CL_{A-C}, and CL_{C-B} parameter values fit from average $[^3]$H-digoxin transport data. The solid line and the broken line represent model fits of the apical dosed and basolateral dosed digoxin transport respectively. ■ and ▲ represent apical and basolateral dosed digoxin data points respectively. Data points presented are the average of 6 transport experiment days ± SE.
Figure 2.10. Model fits of digoxin transwell transport across Caco-2 (0 nM) (A), Caco-2 (10 nM) (B), and Caco-2 (100 nM) (C) cell monolayers out of the donor compartment (I) and into the receiver compartment (II), using Equations 2.1-2.3, with \( CL_{\text{P}-\text{gp}} \), \( CL_{\text{A}-\text{C}} \), and \( CL_{\text{C}-\text{B}} \) parameter values fit from average \(^{3}H\)-digoxin transport data. The solid line ...
and the *broken line* represent model fits of the apical dosed and basolateral dosed digoxin transport respectively. ■ and ▲ represent apical and basolateral dosed digoxin data points respectively. Data points presented are the average of 6 transport experiment days ± SE.
Figure 2.11. Modeled $CL_{p-gp}$ (A), $CL_{A-C}$ (B), $CL_{C-B}$ (C), and $CL_{A-B}$ (D) of bidirectional $[^{3}H]$-digoxin transport for 4 hours across the different cell monolayers. Data are presented as mean ± S.E. ($n \geq 4$). CL values with a different superscript (a, b, or c) are significantly different; $p<0.05$. 
Table 0.3. Estimates of P-gp activity in *LLCPK* and *LMDR1* cell monolayers for each experiment day, evaluated by traditional apparent permeability (\(P_{\text{app}(A-B)}\), \(P_{\text{app}(B-A)}\)) and efflux ratio (EfR) approaches, as well as by P-gp intrinsic clearance (\(CL_{\text{P-gp}}\)) fit from our 3-compartment model. Modeled clearance values for non-P-gp transcellular flux (\(CL_{A-C}\), \(CL_{C-B}\)) and paracellular flux (\(CL_{A-B}\)) are also included for each experiment.

<table>
<thead>
<tr>
<th>Day</th>
<th>Traditional Estimates</th>
<th>Modeled Clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(P_{\text{app}(A-B)})</td>
<td>(P_{\text{app}(B-A)})</td>
</tr>
<tr>
<td></td>
<td>(\times 10^6 \text{ cm/s})</td>
<td>(\times 10^6 \text{ cm/s})</td>
</tr>
<tr>
<td><strong>LLCPK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1.807</td>
<td>2.742</td>
</tr>
<tr>
<td>2</td>
<td>3.045</td>
<td>4.587</td>
</tr>
<tr>
<td>3</td>
<td>1.147</td>
<td>2.052</td>
</tr>
<tr>
<td>4</td>
<td>1.470</td>
<td>2.776</td>
</tr>
<tr>
<td>5</td>
<td>1.442</td>
<td>2.650</td>
</tr>
<tr>
<td>6</td>
<td>1.910</td>
<td>3.015</td>
</tr>
<tr>
<td><strong>Avg</strong></td>
<td><strong>1.804</strong></td>
<td><strong>2.970</strong></td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td><strong>0.272</strong></td>
<td><strong>0.349</strong></td>
</tr>
<tr>
<td><strong>LMDR1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.316</td>
<td>2.952</td>
</tr>
<tr>
<td>2</td>
<td>0.448</td>
<td>3.340</td>
</tr>
<tr>
<td>3</td>
<td>0.352</td>
<td>3.418</td>
</tr>
<tr>
<td>4</td>
<td>0.341</td>
<td>3.087</td>
</tr>
<tr>
<td>5</td>
<td>0.333</td>
<td>3.226</td>
</tr>
<tr>
<td><strong>Avg</strong></td>
<td><strong>0.358</strong></td>
<td><strong>3.2046</strong></td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td><strong>0.023</strong></td>
<td><strong>0.084</strong></td>
</tr>
</tbody>
</table>
Table 0.4. Estimates of P-gp activity in Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) cell monolayers for each experiment day, evaluated by traditional apparent permeability ($P_{\text{app}(A-B)}$, $P_{\text{app}(B-A)}$) and efflux ratio (EfR) approaches, as well as by P-gp intrinsic clearance ($CL_{P-gp}$) fit from our 3-compartment model. Modeled clearance values for non-P-gp transcellular flux ($CL_{A-C}$, $CL_{C-B}$) and paracellular flux ($CL_{A-B}$) are also included for each experiment.

<table>
<thead>
<tr>
<th>Day</th>
<th>Traditional Estimates</th>
<th>Modeled Clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$P_{\text{app}(A-B)} \times 10^6 \text{ cm/s}$</td>
<td>$P_{\text{app}(B-A)} \times 10^6 \text{ cm/s}$</td>
</tr>
<tr>
<td>Caco-2 (0 nM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1.234</td>
<td>2.939</td>
</tr>
<tr>
<td>2</td>
<td>0.806</td>
<td>3.353</td>
</tr>
<tr>
<td>3</td>
<td>1.485</td>
<td>3.304</td>
</tr>
<tr>
<td>4</td>
<td>0.626</td>
<td>3.148</td>
</tr>
<tr>
<td>5</td>
<td>0.799</td>
<td>3.110</td>
</tr>
<tr>
<td>Avg</td>
<td>0.990</td>
<td>3.171</td>
</tr>
<tr>
<td>SD</td>
<td>0.159</td>
<td>0.074</td>
</tr>
<tr>
<td>Caco-2 (10 nM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.275</td>
<td>1.662</td>
</tr>
<tr>
<td>2</td>
<td>0.905</td>
<td>4.113</td>
</tr>
<tr>
<td>3</td>
<td>0.379</td>
<td>2.997</td>
</tr>
<tr>
<td>4</td>
<td>0.46</td>
<td>3.038</td>
</tr>
<tr>
<td>Avg</td>
<td>0.505</td>
<td>2.953</td>
</tr>
<tr>
<td>SD</td>
<td>0.139</td>
<td>0.502</td>
</tr>
<tr>
<td>Caco-2 (100 nM)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.182</td>
<td>3.442</td>
</tr>
<tr>
<td>2</td>
<td>0.539</td>
<td>4.247</td>
</tr>
<tr>
<td>3</td>
<td>0.36</td>
<td>3.761</td>
</tr>
<tr>
<td>4</td>
<td>0.385</td>
<td>3.661</td>
</tr>
<tr>
<td>Avg</td>
<td>0.367</td>
<td>3.778</td>
</tr>
<tr>
<td>SD</td>
<td>0.073</td>
<td>0.170</td>
</tr>
</tbody>
</table>
2.3.6 Predictive performance and sensitivity of P-gp activity metrics

Figures 2.12-2.15 show a linear regression of normalized P-gp activity versus normalized P-gp expression for each metric; Table 2.5 summarizes the outcomes of linear regression analyses. The $r^2$ value for the linear regression of $\text{CL}_{\text{P-gp}}$ activity estimates was over three fold greater and the slope was over six fold greater than the $P_{\text{app}(A-B)}$ and EfR activity estimates. $P_{\text{app}(A-B)}$ and EfR estimates of P-gp activity did both fit a linear regression with P-gp expression, with p-values < 0.05. The difference between modeled clearance and the traditional P-gp activity metrics was far less striking when we focused our analysis on only the subset of data within one cell type (Table 2.5(A) and (B)). Indeed, when we isolated Caco-2 cell expression and flux data for analysis, the $r^2$ values for the linear regressions of EfR and $P_{\text{app}(A-B)}$ activity estimates was less than 2 fold smaller than $\text{CL}_{\text{P-gp}}$ and the slope was actually greater for the EfR linear regression compared to $\text{CL}_{\text{P-gp}}$. When we excluded the Caco-2 cell data the $r^2$ value for the EfR linear regression was greater than $\text{CL}_{\text{P-gp}}$ and $P_{\text{app}(A-B)}$ was only slightly smaller than $\text{CL}_{\text{P-gp}}$. The slope (m) of the $\text{CL}_{\text{P-gp}}$ regression was however, substantially larger than EfR and $P_{\text{app}(A-B)}$ by 4.7 fold and 6.8 fold respectively. $\text{CL}_{\text{P-gp}}$ and EfR linear regressions consistently showed greater $r^2$ and slope compared to $P_{\text{app}(A-B)}$. $P_{\text{app}(B-A)}$ estimates of P-gp activity did not fit a linear regression with P-gp expression in any analysis; the p-value was well above 0.05 for all subsets of data analyzed (Table 2.5).
Figure 2.12. Normalized P-gp protein expression in various transwell monolayer cell types versus the corresponding normalized P-gp transport activity estimates obtained by $P_{\text{app(B-A)}}$ calculation method. P-gp expression was quantified by western blot densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression and activity estimates were normalized respectively to the averaged expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope ($m$) and goodness of fit ($r^2$) are presented for the linear regression of all data sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a non-zero slope is also presented for each linear regression.
Figure 2.13. Normalized P-gp protein expression in various transwell monolayer cell types versus the corresponding normalized P-gp transport activity estimates obtained by $P_{\text{app(B-A)}}$ calculation method. P-gp expression was quantified by western blot densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression and activity estimates were normalized respectively to the averaged expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope ($m$) and goodness of fit ($r^2$) are presented for the linear regression of all data sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a non-zero slope is also presented for each linear regression.
EfR

A

\[ m = 0.1300 \pm 0.04524 \]
\[ r^2 = 0.2730 \]
\[ p < 0.05 \]

LLCPK
LMDR1
Caco-2 (0 nM)
Caco-2 (10 nM)
Caco-2 (100 nM)

B

\[ m = 0.1576 \pm 0.007799 \]
\[ r^2 = 0.9784 \]
\[ p < 0.05 \]

LLCPK
LMDR1

C

\[ m = 1.005 \pm 0.2407 \]
\[ r^2 = 0.6131 \]
\[ p < 0.05 \]

Caco-2 (0 nM)
Caco-2 (10 nM)
Caco-2 (100 nM)
Figure 2.14. Normalized P-gp protein expression in various transwell monolayer cell types versus the corresponding normalized P-gp transport activity estimates obtained by EfR calculation method. P-gp expression was quantified by western blot densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression and activity estimates were normalized respectively to the averaged expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope \((m)\) and goodness of fit \((r^2)\) are presented for the linear regression of all data sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a non-zero slope is also presented for each linear regression.
Figure 2.15. Normalized P-gp protein expression in various transwell monolayer cell types versus the corresponding normalized P-gp transport activity estimates obtained by CL_{P-gp} calculation method. P-gp expression was quantified by western blot densitometry relative to a control Caco-2 cell lysate that was loaded on each blot. Protein expression and activity estimates were normalized respectively to the averaged expression and the averaged estimated activity of the Caco-2 (0 nM) transwell monolayer cells. Slope (m) and goodness of fit (r^2) are presented for the linear regression of all data sets combined (A), only LLCPK and LMDR1 data sets combined (B), and only Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) data sets combined (C). The p-value of the F-test for a non-zero slope is also presented for each linear regression.
Table 0.5. Summary of goodness of fit ($r^2$) and regression slopes (m) for regression analyses of different normalized estimates of P-gp activity with P-gp expression for LLCPK and LMDR1 data sets only (A), Caco-2 (0 nM), (10 nM), and (100 nM) data sets only (B), and all data sets combined (C).

<table>
<thead>
<tr>
<th></th>
<th>$P_{app(A-B)}$</th>
<th>$P_{app(B-A)}$</th>
<th>EfR</th>
<th>$Cl_{P-gp}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r^2$</td>
<td>0.7022</td>
<td>0.03421</td>
<td>0.9784</td>
<td>0.9102</td>
</tr>
<tr>
<td>slope</td>
<td>-0.1091 ± 0.0237</td>
<td>0.0053 ± 0.0094</td>
<td>0.1576 ± 0.0078</td>
<td>0.7465 ± 0.0782</td>
</tr>
<tr>
<td>(B)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r^2$</td>
<td>0.4512</td>
<td>0.1434</td>
<td>0.6131</td>
<td>0.7930</td>
</tr>
<tr>
<td>slope</td>
<td>-0.2689 ± 0.0894</td>
<td>0.0789 ± 0.0581</td>
<td>1.005 ± 0.2407</td>
<td>0.8942 ± 0.1377</td>
</tr>
<tr>
<td>(C)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$r^2$</td>
<td>0.2576</td>
<td>0.005123</td>
<td>0.2730</td>
<td>0.9222</td>
</tr>
<tr>
<td>slope</td>
<td>-0.0749 ± 0.0271</td>
<td>0.0030 ± 0.0089</td>
<td>0.1300 ± 0.0452</td>
<td>0.8086 ± 0.0501</td>
</tr>
</tbody>
</table>
2.4 Discussion

The objective of this study was to compare the validity and sensitivity of a modeled intrinsic clearance against unidirectional apparent permeability and efflux ratio as metrics of P-gp activity across monolayer permeability assay systems. We hypothesized that since modeled clearance measures P-gp activity more directly and specifically, it is superior to apparent permeability and efflux ratio for evaluating P-gp activity in any monolayer permeability assay.

We found that the validity and sensitivity of modeled clearance as a P-gp activity metric is generally on par with efflux ratio and superior to unidirectional apparent permeability for assays conducted in monolayers of a common cell type. But, when making P-gp activity estimates across different cell types, modeled clearance is far superior to the traditional metrics. Indeed, when we separated assays by cell type (Caco-2 (0 nM)/Caco-2 (10 nM)/Caco-2 (100 nM) or LLCPK/LMDR1), the correlation of CL\textsubscript{P-gp}-estimated monolayer P-gp activity vs. measured monolayer P-gp expression had similar or greater slope (sensitivity) and r\textsuperscript{2} value as compared to the correlations of P\textsubscript{app}-estimated P-gp activity vs. P-gp expression and EfR-estimated P-gp activity vs. P-gp expression; but the r\textsuperscript{2} and slope were respectively 3.4-fold and 6.2-fold greater for CL\textsubscript{P-gp} when we evaluated the combined data from both cell types together.

Caco-2, LMDR1, and MDCK-MDR1 cells are all commonly used for cell monolayer permeability assays (11-14). Some level of polarized apical P-gp expression has been demonstrated in each of these cell types, such that they can all be used to demonstrate substrates or modulators of P-gp activity in vitro. Previous reports though, found that relative P-gp expression differs between Caco-2, MDCK-MDR1 (not included in our study), LLCPK, and LMDR1 cell types (15; 16), which agreed with the western blot findings in our study. Our blots also agreed with previous studies that have reported a concentration-dependent increase in P-gp expression in Caco-2 cells treated with vitamin D (17; 18). Some models of intestinal absorption and metabolism rely on vitamin D treatment to induce CYP3A4 activity in Caco-2 monolayers. So, LLCPK, LMDR1 and Caco-2 cells and Caco-2 cells treated with vitamin D are all commonly utilized in cell-based models and assays of permeability; and because of their inherent differences in P-
gp expression, our study had a suitable range of cell monolayer P-gp expression across which to examine the validity and sensitivity of P-gp activity metrics.

The level of P-gp expression in a given monolayer cell system dictates the level of P-gp efflux activity. Accordingly, from cursory assessment of our transport data there is evidence of increasing efflux transport – marked by increasing basolateral to apical disparity in bidirectional flux – in the rank orders LLCPK<LMDR1 and Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100 nM), which paralleled the rank orders of cell monolayer P-gp expression. In our study though, the basolateral to apical apparent permeability did not demonstrate this relationship with cell monolayer P-gp expression. We found no correlation between $P_{\text{app}}(B-A)$ and P-gp expression in Caco-2 cells, in LLCPK/LMDR1 cells, or in Caco-2 and LLCPK/LMDR1 cells. This result conflicted with previous studies by Taipalensuu et al. and Hayeshi et al., who reported correlation between Caco-2 cell P-gp expression and both basolateral to apical apparent permeability and efflux ratio (14; 19). Possible explanation for our conflicting results could relate to plastic adsorption in the basolateral compartment or cellular retention of drug passing through the cell from the basolateral compartment into the apical compartment. Youdim et al., suggests that traditional permeability equations fail to account for cellular retention (20). The loss of drug to cellular retention and plastic adsorption during transport experiments could certainly lead to false measurements of a drug’s permeability value (20-22). Our model exercise does suggest though that lack of correlation between $P_{\text{app}}(B-A)$ with P-gp expression is most likely due to the fact that digoxin permeability at the basolateral membrane is significantly lower than efflux activity at the apical membrane. This indicates that overall basolateral to apical digoxin transcellular flux is rate-limited by basolateral membrane permeation rather than P-gp activity. However, the $P_{\text{app}}(A-B)$ and EfR values calculated in our experiments did show a correlation with P-gp expression in Caco-2 cells, which agreed with previous studies (14; 19). Similarly in LLCPK/LMDR1 cells we also saw correlation between $P_{\text{app}}(A-B)$ and P-gp expression and between EfR and LLCPK/LMDR1 cells.

In explaining why CL$_{P-gp}$ reflects P-gp activity more predictably and sensitively when comparing between cell types, we believe this relates not to difference in P-gp expression
between cell types, but to differences in non-P-gp transporters and cell morphology that also contribute to drug transit. Aside from P-gp, Caco-2 cells, LMDR1 cells, and MDCK-MDR1 cells have all been reported to show different relative expression levels of several transporters, including but not limited to: MRP2, and BCRP apical efflux transporters, peptide transporter 1 (PepT1) apical uptake transporter, multidrug resistance-associated protein 3 (MRP3), MRP1, and organic solute transporter-α and -β (OST-α and -β) basolateral efflux transporters and OATP-A (SLC21A3), OATP-C (SLC21A6), and OATP-B (SLC21A9) basolateral uptake transporters (23-30; 19). Many of these transporters have overlapping substrate specificities with P-gp and thus multiple transporters may contribute, to varying degrees in different monolayers, to the flux of any given drug that is being tested for specific interaction with P-gp. As Sun and Pang demonstrated in a theoretical study, the presence of other active transport has the potential to overcome the effect of P-gp apical efflux activity, which could result in the over- or under-estimation of traditional monolayer permeability metrics of P-gp activity (9). This may even apply to the prototypical P-gp probe substrate, digoxin. Some non-P-gp transporters have been previously implicated in digoxin transcellular flux across assay monolayers. Sun and Pang’s theoretical study predicted the kinetic presence of a basolateral digoxin uptake transporter in Caco-2 cells and there has been evidence in MDCK cells of active basolateral uptake of digoxin that is inhibited by GF120918 (9; 31). There have also been reports that digoxin is transported by OST-α and -β (32), which is expressed in Caco-2 cells. There is a clear potential for other transporters to obscure the monolayer permeability that P_app and EfR attribute solely to P-gp activity. Yet, though many transporters may contribute to flux across Caco-2, LLCPK or MDCK monolayers, we are not aware of any comprehensive studies in the literature that directly compare transporter expression patterns between these cells. Difficulty assessing differences in transporter expression among these cells lines will be compounded by species-related differences in transporter activity towards specific substrates. Consequently, it is difficult even to anticipate the relative impact of different transporters on monolayer transit between cell lines; so, it is hard to know how much P_app or EfR measured in a given cell type may be over- or under-estimating P-gp activity.
While the non-P-gp transporter differences are overlooked in the calculation of EfR and $P_{app}$ as estimates of P-gp activity, in our modeled clearance the general effects of non-P-gp transporter difference are imbedded within the fitted $CL_{A-C}$ and $CL_{C-B}$ parameters. The difference that we observed between the $CL_{A-C}$ and $CL_{C-B}$ parameters fitted from Caco-2 data versus LLCPK/LMDR1 data seem to reflect the reported difference in non-P-gp transport activity between Caco-2 and LLCPK/LMDR1 cells.

Although transporter differences between cell lines may not have been compared in great detail, certain morphological differences between Caco-2, LLCPK, and MDCK cells have been documented. Caco-2 cells, for example, are well known to form in vitro monolayers with greater integrity and lower transepithelial electrical resistance (TEER) than MDCK cells (33). In their theoretical study, Sun and Pang demonstrated the potential for paracellular flux to obscure apical efflux (9). Since paracellular transit differs between cell types, as was also demonstrated in our study by measurement of the paracellular marker $[^{14}C]$-inulin, the degree to which paracellular flux obscures the $P_{app}$ and EfR estimations of P-gp also differs between cell types. For our model $CL_{P-gp}$, however, the difference between Caco-2 and LLCPK/LMDR1 paracellular $[^3H]$-digoxin transit is imbedded in the $CL_{A-B}$ parameter. Therefore, the $CL_{P-gp}$ estimate of P-gp activity derived from any monolayer assay is, theoretically, independent of the integrity characteristics of a particular monolayer.

Transporter and morphological differences between cell types, or even within a cell type, can be further complicated by differences in laboratory practice. Owing to the intrinsic heterogeneity of the parental Caco-2, LLCPK and MDCK cell lines, culture-related conditions have been shown to influence the morphological and functional characteristics of in vitro monolayers, by selecting for sub populations of cells in culture (34). Variability has been previously reported in Caco-2 cell paracellular permeability and transporter expression (35; 36) and has been ascribed to difference in culture conditions, passage number and cell source (37-39; 19). This results in significant variability in the estimates of P-gp activity calculated by $P_{app}$ or EfR, even in the same in vitro system and cell type (40). In effect, the value of the monolayer permeability assay for assessing P-gp activity and IVIVE becomes limited when we use $P_{app}$ or EfR for any moderate substrate
of P-gp that has broad transporter specificity or high passive permeability. By specifically isolating the activity of P-gp transporter from the other active and passive transport processes in a monolayer permeability assay, $\text{CL}_{\text{P-gp}}$ is able to effectively extract more widely useable data for any laboratory working with their preferred assay conditions.
2.5 References


Chapter 3
General Discussion

3.1 Study Objective

The objective of this study was to compare the validity and sensitivity of unidirectional apparent permeability and efflux ratio against modeled intrinsic clearance, as metrics of P-gp activity in the monolayer permeability assay. Our rationale was that $P_{\text{app}}$ and EfR only provide a qualitative estimate of P-gp activity from general drug flux across an assay monolayer, whereas $\text{CL}_{\text{P-gp}}$ quantitatively estimates specific P-gp-mediated efflux from the cell compartment at the apical membrane. Therefore, the mechanistically based estimate would be expected to be more sensitive and valid across cell systems and variable laboratory assay conditions. Moreover, $\text{CL}_{\text{P-gp}}$ provides quantitative values that can be directly applied for IVIVE, unlike $P_{\text{app}}$ and EfR. No prior studies have compared these P-gp activity metrics across different commonly used assay cell systems. Here, our main objective was to obtain experimental data to prove that modeled clearance estimates P-gp activity better than $P_{\text{app}}$ and EfR across monolayer permeability assay cell types.

3.2 Monolayer permeability assay metrics of P-gp activity

We compared the P-gp activity metrics across various cell types because, although Caco-2, LLCPK and MDCK cells can all form an in vitro monolayer with polarized P-gp expression, in vitro monolayers composed of these cell types differ in ways that fundamentally affect the transit of test drugs. Our experiment cells differed in P-gp expression in the rank order LLCPK < Caco-2 (0 nM) < Caco-2 (10 nM) < Caco-2 (100 nM) < LMDR1, and since, in theory, P-gp transport activity is directly proportional to P-gp expression, valid and useful transport activity metrics could be evaluated using data from all experimental groups. It would appear that $P_{\text{app}(A-B)}$, EfR and $\text{CL}_{\text{P-gp}}$ are all valid metrics of P-gp activity when estimates are made within a common cell type (eg. in Caco-2 (0 nM)/Caco-2 (10 nM)/Caco-2 (100 nM) or LLCPK/LMDR1); we found good correlation between monolayer P-gp expression and respectively $P_{\text{app}(A-B)}$, EfR, and $\text{CL}_{\text{P-gp}}$ estimates of monolayer P-gp activity. However, unidirectional apparent permeability and efflux ratio are not good metrics when estimating monolayer P-gp activity across
different cell types; poor correlation was shown between monolayer P-gp expression and respective $P_{\text{app}}$ and EfR estimates of P-gp activity. Unidirectional apparent permeability and efflux ratio simplify transit across the monolayer as movement across a single barrier driven only by P-gp transport (1-4). Our investigation suggests that this approximation was adequate when estimating different P-gp activities within one cell type because the action of the P-gp transporter alone was responsible for much of the difference seen in [³H]-digoxin bidirectional flux between Caco-2 (0 nM), Caco-2 (10 nM), and Caco-2 (100 nM) cell monolayers and between LLCPK and LMDR1 monolayers. But, difference in isolated P-gp transport activity across a single barrier was not sufficient on its own to account for the difference seen in [³H]-digoxin flux between LLCPK, Caco-2 (0 nM), Caco-2 (10 nM), Caco-2 (100 nM), and LMDR1 monolayers. We conclude neither $P_{\text{app}}$ nor EfR are valid metrics of P-gp activity when comparing across cell types.

Conversely, we found our modeled $CL_{P_{\text{gp}}}$ is well suited to estimate P-gp activity within and across cell types; with good correlation for all linear regression analyses. Our compartmental model includes $CL_{C-B}$ and $CL_{A-C}$ to account for both passive and active transport processes occurring in both directions across the basolateral and apical membranes respectively. Thus, these parameters are able to account for non-P-gp transporters on either membrane, which may contribute significantly to differences in monolayer transit observed between monolayer cell types because Caco-2, LLCPK and MDCK cells all show different transporter expression in vitro (1; 5-12). The model fitted $CL_{C-B}$ and $CL_{A-C}$ parameters reflected the difference in non-P-gp transporter expression between LLCPK/LMDR1 and Caco-2 cell types. Our model also includes $CL_{A-B}$ to account for variable paracellular transit, which results from differences in monolayer integrity that have been well documented between monolayer cell types (13; 14). By accounting for all of these confounding processes, $CL_{P_{\text{gp}}}$ is able to tease out the specific contribution of P-gp-mediated transport across all assays. In our investigation, modeled clearance has proven to be a valid metric of P-gp activity between monolayer permeability assay cell types.

Another ideal property of a quantitative metric for P-gp activity is sensitivity to varying levels of P-gp expression and function. The relative sensitivity of metrics can be
evaluated by comparing the slopes (m) of the relationships between normalized P-gp activity and P-gp expression either within a cell type or with combined cell types. When considering results from combined Caco-2 and LLCPK cells, the rank order of slope values are $P_{\text{app(B-A)}} < P_{\text{app(A-B)}} < \text{EfR} < \text{CL}_{\text{P-gp}}$. This indicates that across cell systems, CL$_{\text{P-gp}}$ is the most sensitive P-gp activity metric. However, within the LLCPK/LMDR1 system, slope values suggest that EfR is the most sensitive P-gp activity metric. CL$_{\text{P-gp}}$ was the most sensitive measure of P-gp activity when evaluating data within the Caco-2 system.

3.3 Standardizing monolayer permeability assays

Given the importance of P-gp in the absorption, distribution, and excretion of drugs, it is essential to have in vitro assays that are capable of assessing potential P-gp interactions. A variety of biological systems are available to assess the potential for these interactions, including ATPase assays, fluorescent assays, and membrane vesicles. But, monolayer permeability assays are recommended as the most direct measure of P-gp activity (15-20). For this reason, academic, industry, and regulatory laboratories regularly conduct monolayer permeability assays on drugs to test for P-gp interaction using the standard transwell set-up. But, there is great potential for individual laboratories to introduce variability into this assay, which can make it challenging to draw congruent pharmacokinetic conclusions from the same assay conducted in different laboratories.

First, as previously mentioned there is not one standard cell type used to compose the monolayer; Caco-2, LLCPK, or MDCK are all commonly interchanged. Although each of these cell types will spontaneously differentiate in vitro to form a monolayer with polarized apical P-gp expression (21-24), we have clearly demonstrated in our study the inherent challenge of trying to draw compatible conclusions about P-gp activity from multiple monolayer cell types.

Moreover, owing to the inherent heterogeneity of the parent Caco-2, LLCPK, and MDCK cell lines, lack of standardization in laboratory practice can amplify variability in the permeability assay systems applied by different groups, regardless of chosen cell type. There is significant inter-lab variability in culture conditions, transwell equipment, cell
sources, cell passage number, seeding density, and bioanalytical techniques (25-28; 12). Many labs gauge monolayer integrity by measuring TEER, while others use mannitol, inulin, or Lucifer yellow flux. Furthermore, the monolayer integrity acceptance criteria vary substantially even for labs using the same measure. Some laboratories conduct transport experiments on a shaker, while others do not. The components of the culture media and assay buffers may vary between labs as well. Many labs also have their own protocol for seeding density and culture time of monolayer cells. Even plate and well insert sources vary, as well as insert pore size. A comparative study looking at inter-lab variability across 23 research laboratories and academic institutions found that 80% of variability in P-gp IC50 estimates was due to the use of different laboratory practices (28).

Consistency in the conclusions drawn about P-gp activity from monolayer permeability assays, performed under such diverse conditions, necessitates either strict standardization of assay protocols or a method of interpreting assay data that accounts for as much of the assay variability as possible. Sambuy et al. performed an interlaboratory study of mannitol permeability and TEER in Caco-2 cells with the goal of establishing a standardized protocol that would allow meaningful comparison of results obtained in different laboratories (29). We are not aware of any similar initiatives and none that address variability in non-P-gp transporter expression, which contributes to substrate transcellular flux variation. In this study though, we have explicitly demonstrated the capability of modeled clearance to yield a standard P-gp activity output, at very least, for the monolayer permeability assay variability that results from using different cell types. In principle, this model should extend to standardize P-gp activity estimation for a variety of different sources of assay variability.

3.4 Applying monolayer permeability assay data to drug discovery and development

The output of monolayer permeability assays are meant to provide information about whether a drug is a substrate of P-gp or the potential for P-gp mediated DDIs. Particularly in the DDD process, monolayer permeability assays provide important preclinical information in the early stages of drug candidate investigation that decides subsequent in
*vivo* and clinical testing (15; 30-38). At these early stages though, the major role of monolayer permeability assay is just to provide a qualitative yes or no assessment of whether or not a drug is a substrate or inhibitor of P-gp. If yes, then more in-depth study is conducted on the PK effects and potential DDIs. For this qualitative assessment, standardization of assay cell types or conditions may not be crucial. $P_{\text{app}}$ or EfR results may show some variation between labs, but in practice, a compound with a measured EfR of 10 in one lab that has a measured EfR of 12 in another lab will be assessed as a P-gp substrate in either case. An issue arises however, for drugs that show only moderate interaction with P-gp. For these drugs, close consensus would be required between $P_{\text{app}}$ or EfR estimates of P-gp activity made in different labs in order for the drug-P-gp interaction to be harmoniously defined across laboratories. There have been reports of drugs that appear as P-gp substrate in a Caco-2 assay, but not in a MDCK-MDR1 assay (39). The consequence of a false negative or a false positive can be respectively, a failure to conduct appropriate follow-up tests to collect critical PK information, or performing needless subsequent studies that do not yield significant *in vivo* or clinical relevance. CL_{P-gp} is very important for its ability to bring consensus to the interpretation of P-gp interactions made using monolayer permeability assays in different laboratories.

### 3.5 Applying monolayer permeability assay data to IVIVE

Although the use of monolayer permeability assays recommended by regulatory agencies in the early stages of DDD focuses more on simple identification of P-gp substrates and inhibitors, there is substantial interest in industry and academia in more detailed characterization of P-gp interactions because of its important role in absorption, distribution and excretion pharmacokinetics (30; 40; 41). Therefore, monolayer permeability assays are also used as an important tool in *in vitro* to *in vivo* extrapolation (IVIVE).

A drug that is identified as a substantial P-gp substrate by $P_{\text{app}}$ or EfR, with an EfR of 20 for example, will then qualitatively be expected to show reduced clinical oral absorption because of broad P-gp expression in the intestines. In order to make any quantitative prediction from the monolayer permeability assay though, data must be properly interpreted to characterize the P-gp activity in a physiologically relevant way.
CL_{P-gp} not only serves as a consensus metric of P-gp activity in monolayer permeability assays, but it provides a quantitative and physiologically relevant assessment of P-gp activity that can be applied directly to quantitative IVIVE. It is particularly useful for quantitative IVIVE because it specifically characterizes P-gp transport activity from the intracellular space, where P-gp accesses substrate. Characterizing P-gp transporter kinetics directly from flux data would be simplifying the system as a single barrier with only P-gp activity, which would only yield apparent kinetics for P-gp. In reality there are several other kinetic processes contributing to flux across the monolayer, the most important of which are described in our 3 compartmental model (42-47).

The physiological relevance of CL_{P-gp} makes it appropriate for application in physiologically-based pharmacokinetic (PBPK) models. These models, as we have described, incorporate chemical information about compounds and physiological and in vitro kinetic information into anatomically arranged compartments. Intrinsic clearance, defined as the perfusion-rate-independent clearance of a drug from a system by the cumulative intrinsic activities of the contributing drug metabolizing enzymes and/or transporters, is an essential component of these models. For drug metabolizing enzymes, intrinsic clearance can be characterized from the metabolism kinetics in isolated hepatocyte, microsomal fractions, or recombinant enzyme systems (15; 48-50). For uptake transporters, it can be described from uptake kinetics in isolated hepatocytes or recombinant cell lines (51; 50). With the modeled clearance we describe here in our study, we can produce the intrinsic clearance input for PBPK model efflux transporters from the conventional monolayer permeability assay. In the context of a PBPK, which incorporates all of the dynamically acting ADME proteins and physiological processes, we can understand drugs that appear to interact with P-gp in the monolayer permeability assay but do not necessarily demonstrate clinical P-gp interaction because of the overlapping in vivo activity of other ADME enzymes (52).

3.6 Limitations of the experimental approach to estimate CL_{P-gp} (model assumptions)

1. All transwell transport experiments were assumed to operate exclusively under linear conditions in our model.
2. We assumed there were no spatial variations in pH or concentration intracellularly.

3. Our steady state model of transport assumes mass balance of drug in the system, when in fact drug is removed during multiple sampling.

4. We assumed that digoxin is not subject to any significant metabolism.

5. We assumed that neither digoxin, nor inulin were subject to any significant protein or plastic binding in the transwells.

6. We simplified the complexity of the model in order to successfully fit the data, by assuming that digoxin clearance was equal in both directions across the apical membrane and equal in both directions across the basolateral membrane.

3.7 Recommendations/future studies

1. In our studies, we investigated P-gp efflux with 2 commonly used monolayer cell types (Caco-2 and LLCPK). In a future study, it would be interesting to include P-gp activity estimates made in MDCK/MDCK-MDR1 monolayers to the linear regression analysis, to confirm that the validity and sensitivity of CL\textsubscript{P-gp} as a P-gp metric extends to this third commonly used monolayer cell type.

2. Similarly, it would be interesting to include monolayer assays conducted with varied protocols to the linear regression analysis, to see how well our model isolates P-gp activity and accounts for monolayer difference produced by variable laboratory practices.

3. We used the gold standard P-gp probe drug, digoxin, for our study, but future studies may investigate P\textsubscript{app}, EfR and CL\textsubscript{P-gp} monolayer permeability assay metrics for other P-gp substrates that may show different permeability or may be less specific to the P-gp transporter.

4. It would be interesting as well to consider effects of P-gp inhibition by drugs and effects on P-gp activity metrics. For example, examining which activity metric is
most sensitive in estimating the inhibitory constant (Ki) for P-gp for a given test drug whose co-administration affects the flux of digoxin in a transwell system.

5. Finally, estimation of absolute P-gp intrinsic activity of P-gp with digoxin using absolute quantification of P-gp by LC-MS/MS would provide critical information for IVIVE.

3.8 Overall conclusion

In conclusion, our findings support our hypothesis that CL_{P-gp} offers a more valid and sensitive estimate of P-gp activity in the monolayer permeability assay, particularly for comparison across different monolayer cell types. The traditional metrics, P_{app} and EfR do not relate well across the many variations of monolayer permeability assay that exist and thus the conclusions drawn by these metrics have limited global value. Conversely, we found that modeled clearance, CL_{P-gp}, seems to account for non-P-gp transcellular and paracellular processes that contribute to monolayer transit, thus providing a more physiologically relevant characterization of P-gp transporter activity. Many efflux transporters, particularly P-glycoprotein, play an important role in drug pharmacokinetics and disposition and in vitro characterization of P-gp activity is very important to understanding drug PK and DDIs (30; 40; 41). Modeled clearance provides more physiologically relevant information that can be used for understanding and predicting clinical pharmacokinetics for more successful drug therapy.
3.9 References


32. Hsiao P, Bui T, Ho RJ, Unadkat JD (2007) In vitro to in vivo prediction of p-glycoprotein based drug interactions at the human and rodent blood-brain barrier. Drug Metabolism and Disposition 34: 786–792


cer-ivastatin and cyclosporin A. Journal of Pharmacology and Experimental Therapeutics 304: 610–616

Curriculum Vitae

Name: Alex D. Morgan

Post-secondary Education and Degrees:
University of Western Ontario
London, Ontario, Canada
2005-2009 B.MSc.
The University of Western Ontario
London, Ontario, Canada

Honours and Awards:
Frederick Banting and Charles Best Canada Graduate Scholarship
Awards: 2010-2011

Abstracts Submitted:


